CA2330207C - Microneedle devices and methods of manufacture and use thereof - Google Patents
Microneedle devices and methods of manufacture and use thereof Download PDFInfo
- Publication number
- CA2330207C CA2330207C CA002330207A CA2330207A CA2330207C CA 2330207 C CA2330207 C CA 2330207C CA 002330207 A CA002330207 A CA 002330207A CA 2330207 A CA2330207 A CA 2330207A CA 2330207 C CA2330207 C CA 2330207C
- Authority
- CA
- Canada
- Prior art keywords
- microneedles
- microneedle
- silicon
- skin
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B81—MICROSTRUCTURAL TECHNOLOGY
- B81C—PROCESSES OR APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OR TREATMENT OF MICROSTRUCTURAL DEVICES OR SYSTEMS
- B81C1/00—Manufacture or treatment of devices or systems in or on a substrate
- B81C1/00015—Manufacture or treatment of devices or systems in or on a substrate for manufacturing microsystems
- B81C1/00023—Manufacture or treatment of devices or systems in or on a substrate for manufacturing microsystems without movable or flexible elements
- B81C1/00111—Tips, pillars, i.e. raised structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150274—Manufacture or production processes or steps for blood sampling devices
- A61B5/150282—Manufacture or production processes or steps for blood sampling devices for piercing elements, e.g. blade, lancet, canula, needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150977—Arrays of piercing elements for simultaneous piercing
- A61B5/150984—Microneedles or microblades
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B81—MICROSTRUCTURAL TECHNOLOGY
- B81B—MICROSTRUCTURAL DEVICES OR SYSTEMS, e.g. MICROMECHANICAL DEVICES
- B81B2201/00—Specific applications of microelectromechanical systems
- B81B2201/05—Microfluidics
- B81B2201/055—Microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Manufacturing & Machinery (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Anesthesiology (AREA)
- Optics & Photonics (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicinal Preparation (AREA)
Abstract
Microneedle devices for transport of therapeutic and diagnostic materials and/or energy across tissue barriers, and methods for manufacturing the devices, are provided. The microneedles are hollow and/or porous and have diameters between about l0nm and lmm. The microneedle devices permit drug delivery (or removal or sensing of body fluids) at clinically relevant rates across skin or other tissue barriers, without damage, pain, or irritation to the tissue. Microfabrication techniques are used to cost-effectively produce arrays of microneedles from metals, silicon, silicon dioxide, ceramic, and polymeric materials. Methods are provided for making porous or hollow microneedles.
Description
MICRONEEDLE DEVICES
AND METHODS OF MANUFACTURE AND USE THEREOF
Background of the Invention This invention is generally in the field of devices for the transport of therapeutic or biological molecules across tissue barriers, such as for drug delivery.
Numerous drugs and therapeutic agents have been developed in the battle against disease and illness. However, a. frequent limitation of these drugs is their delivery, how to transport drugs across biological barners in the body (e.g., the skin, the oral mucosa, the blood-brain barrier), which :normally do not transport drugs at rates that are therapeutically useful or optimal.
Drugs are commonly administered orally as pills or capsules. However, many drugs cannot be effectively delivered in this manner, due to degradation in the gastrointestinal tract and/or elimination by the liver. Moreover, some drugs cannot effectively diffuse across the intestinal mucosa. Patient compliance may also be a problem, for example, in therapies requiring that pills be taken at particular intervals over a prolonged time.
Another common technique for delivering drugs across a biological barrier is the use of a needle, such as those used with standard syringes or catheters, to transport drugs across (through) the skin. While effective for this purpose, needles generally cause pain;
local damage to the skin at the :>ite of insertion; bleeding, which increases the risk of disease transmission; and a wound sufficiently large to be a site of infection. The withdrawal of bodily fluids, such as for diagnostic purposes, using a conventional needle has these same disadvantages. Needle techniques also generally require administration by one trained in its use. The needlle technique also is undesirable for long term, controlled ~;5 continuous drug delivery.
Similarly, current methods of sampling biological fluids are invasive and suffer from the same disadvantages. 1 or example, needles are not preferred for frequent routine use, such as sampling of a diabetic's blood glucose or delivery of insulin, due to the vascular damage caused by repeated punctures. No alternative methodologies are :40 currently in use. Proposed alternatives to the needle require the use of lasers or heat to create a hole in the skin, which is inconvenient, expensive, or undesirable for repeated use.
An alternative delivery technique is the transdermal patch, which usually relies on diffusion of the drug across the skin. However, this method is not useful for many drugs, due to the poor permeability (i.e. effective barrier properties) of the skin.
The rate of diffusion depends in part on thc~ size and hydrophilicity of the drug molecules and the concentration gradient across the stratum cornewn. F ew drugs have the necessary physiochemical properties to be effectively delivered through the skin by passive diffusion. Iontophoresis, electnoporation, ultrasound, and heat (so-called active systems) 1l0 have been used in an attempt to improve the rate of delivery. While providing varying degrees of enhancement, these techniques are not suitable for all types of drugs, failing to provide the desired level of delivery. In some cases, they are also painful and inconvenient or impractical for continuous controlled drug delivery over a period of hows or days. Attempts have been made to design alternative devices for active transfer of l5 drugs, or analyte to be measwed, through the skin.
For example, U.S. Patent No. 5,879,326 to Godshall et al. and PCT WO 96/37256 by Silicon Microdevices, Inc. disclose a transdermal drug delivery apparatus that includes a cutter portion having a plwaliity of microprotrusions, which have straight sidewalls, extending from a substrate that is in communication with a drug reservoir. In operation, :'0 the microprotrusions penetrate the skin until limited by a stop region of the substrate and then are moved parallel to the skin to create incisions. Because the microprotrusions are dragged across the skin, the device creates a wound sufficiently large to be a site of infection. Channels in the substrate adjacent to the microprotrusions allow drug from the reservoir to flow to the skin ne,~r the area disrupted by the microprotrusions. Merely :?5 creating a wound, rather than using a needle which conveys drug through an enclased channel into the site of administration, also creates more variability in dosage.
U.S. Patent No. 5,250,023 to Lee et al. discloses a transdermal drug delivery device, which includes a plwality of skin needles having a diameter in the range of 50 to 400 l.tm. The skin needles are supported in a water-swellable polymer substrate through ;30 which a drug solution permeates to contact the surface of the skin. An electric current is applied to the device to open the pathways created by the skin needles, following their withdrawal from the skin upon swelling of the polymer substrate.
PCT w0 93/17754 by Gross et a1. discloses another transdermal drug delivery device that includes a housing having a liquid drug reservoir and a plurality of tubular elements for transporting liquid drug into the skin. The tubular elements may be in the form of hollow needles having inner diameters of less than lmm and an outer diameter of l.Omm.
While each of these devices has potential use, there remains a need for better drug delivery devices, which make smaller incisions, deliver drug with greater efficiency (greater drug delivery per quantity applied) and less variability of drug administration, and/or are easier to use.
It is an object of embodiments of the present invention to provide a microneedle device for relatively painless, controlled, safe, convenient transdermal delivery of a variety of drugs.
Another object of embodiments of the present invention is to provide a microneedle device for controlled sampling of biological fluids in a minimally-invasive, painless, and convenient manner.
Another object of embodiments of the present invention is to provide a hollow microneedle array for use in delivery or sensing of drugs or biological fluids or molecules.
AND METHODS OF MANUFACTURE AND USE THEREOF
Background of the Invention This invention is generally in the field of devices for the transport of therapeutic or biological molecules across tissue barriers, such as for drug delivery.
Numerous drugs and therapeutic agents have been developed in the battle against disease and illness. However, a. frequent limitation of these drugs is their delivery, how to transport drugs across biological barners in the body (e.g., the skin, the oral mucosa, the blood-brain barrier), which :normally do not transport drugs at rates that are therapeutically useful or optimal.
Drugs are commonly administered orally as pills or capsules. However, many drugs cannot be effectively delivered in this manner, due to degradation in the gastrointestinal tract and/or elimination by the liver. Moreover, some drugs cannot effectively diffuse across the intestinal mucosa. Patient compliance may also be a problem, for example, in therapies requiring that pills be taken at particular intervals over a prolonged time.
Another common technique for delivering drugs across a biological barrier is the use of a needle, such as those used with standard syringes or catheters, to transport drugs across (through) the skin. While effective for this purpose, needles generally cause pain;
local damage to the skin at the :>ite of insertion; bleeding, which increases the risk of disease transmission; and a wound sufficiently large to be a site of infection. The withdrawal of bodily fluids, such as for diagnostic purposes, using a conventional needle has these same disadvantages. Needle techniques also generally require administration by one trained in its use. The needlle technique also is undesirable for long term, controlled ~;5 continuous drug delivery.
Similarly, current methods of sampling biological fluids are invasive and suffer from the same disadvantages. 1 or example, needles are not preferred for frequent routine use, such as sampling of a diabetic's blood glucose or delivery of insulin, due to the vascular damage caused by repeated punctures. No alternative methodologies are :40 currently in use. Proposed alternatives to the needle require the use of lasers or heat to create a hole in the skin, which is inconvenient, expensive, or undesirable for repeated use.
An alternative delivery technique is the transdermal patch, which usually relies on diffusion of the drug across the skin. However, this method is not useful for many drugs, due to the poor permeability (i.e. effective barrier properties) of the skin.
The rate of diffusion depends in part on thc~ size and hydrophilicity of the drug molecules and the concentration gradient across the stratum cornewn. F ew drugs have the necessary physiochemical properties to be effectively delivered through the skin by passive diffusion. Iontophoresis, electnoporation, ultrasound, and heat (so-called active systems) 1l0 have been used in an attempt to improve the rate of delivery. While providing varying degrees of enhancement, these techniques are not suitable for all types of drugs, failing to provide the desired level of delivery. In some cases, they are also painful and inconvenient or impractical for continuous controlled drug delivery over a period of hows or days. Attempts have been made to design alternative devices for active transfer of l5 drugs, or analyte to be measwed, through the skin.
For example, U.S. Patent No. 5,879,326 to Godshall et al. and PCT WO 96/37256 by Silicon Microdevices, Inc. disclose a transdermal drug delivery apparatus that includes a cutter portion having a plwaliity of microprotrusions, which have straight sidewalls, extending from a substrate that is in communication with a drug reservoir. In operation, :'0 the microprotrusions penetrate the skin until limited by a stop region of the substrate and then are moved parallel to the skin to create incisions. Because the microprotrusions are dragged across the skin, the device creates a wound sufficiently large to be a site of infection. Channels in the substrate adjacent to the microprotrusions allow drug from the reservoir to flow to the skin ne,~r the area disrupted by the microprotrusions. Merely :?5 creating a wound, rather than using a needle which conveys drug through an enclased channel into the site of administration, also creates more variability in dosage.
U.S. Patent No. 5,250,023 to Lee et al. discloses a transdermal drug delivery device, which includes a plwality of skin needles having a diameter in the range of 50 to 400 l.tm. The skin needles are supported in a water-swellable polymer substrate through ;30 which a drug solution permeates to contact the surface of the skin. An electric current is applied to the device to open the pathways created by the skin needles, following their withdrawal from the skin upon swelling of the polymer substrate.
PCT w0 93/17754 by Gross et a1. discloses another transdermal drug delivery device that includes a housing having a liquid drug reservoir and a plurality of tubular elements for transporting liquid drug into the skin. The tubular elements may be in the form of hollow needles having inner diameters of less than lmm and an outer diameter of l.Omm.
While each of these devices has potential use, there remains a need for better drug delivery devices, which make smaller incisions, deliver drug with greater efficiency (greater drug delivery per quantity applied) and less variability of drug administration, and/or are easier to use.
It is an object of embodiments of the present invention to provide a microneedle device for relatively painless, controlled, safe, convenient transdermal delivery of a variety of drugs.
Another object of embodiments of the present invention is to provide a microneedle device for controlled sampling of biological fluids in a minimally-invasive, painless, and convenient manner.
Another object of embodiments of the present invention is to provide a hollow microneedle array for use in delivery or sensing of drugs or biological fluids or molecules.
Summary of the Invention Microneedle devices for transport of molecules, including drugs and biological molecules, across tissue, and methods for manufacturing the devices are provided.
According to the present invention, a device for transport of material or energy across biological barriers comprises a plurality of hollow microneedles having a length between 100um and 1mm, and a substrate to which the microneedles are attached or integrally formed, the microneedles extending at an angle from the substrate, wherein the microneedles are made by a microfabrication technique from a material selected from the group consisting of silicon, silicon dioxide, metals, ceramics, and combinations thereof, and wherein each microneedle has a shaft, a portion of which comprises one or more substantially annular bores or channels therethrough and which has a width between about 1um and 100um.
The microneedle devices of embodiments of the invention permit drug delivery or removal of body fluids at clinically relevant rates across skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue. Microneedles can be formed of a variety of materials, including biodegradable or non-biodegradable polymeric materials or metals. In one preferred embodiment, the device includes a means for temporarily securing the microneedle device to the biological barrier to facilitate transport. The device preferably further includes a means for controlling the flow of material through the microneedles. Representative examples of these means include the use of permeable membranes, fracturable impermeable membranes, valves, and pumps, and electrical means.
3a WO 99/645$0 PCT/US99/13226 Methods are provided l:or making solid, porous, or, preferably, hollow microneedles. A preferred method for making a microneedle includes forming a micromold having sidewalls which define the outer surface of the microneedle.
The micromold can be formed, for example, by photolithographically defining one or more holes in a substrate, or by laser based cutting (either serially or by using lithographic projection), or by using a moldl-insert. In a preferred embodiment, the method includes electroplating the sidewalls to form the hollow microneedle, and then removing the micromold from the microneedle.
The microneedle device is useful for delivery of fluid material into or acrass a biological barrier such as skin, wherein the fluid material is delivered from one or more chambers in fluid connection vvith at least one of the microneedles.
Brief Description Of The Drawings Figure 1 is a side eleva~tional view of a preferred embodiment of the microneedle device inserted into human ski .
Figures 2a-a are side cross-sectional views of a method for making microneedles.
Figures 3a-g are side cross-sectional views of a method for making a hollow microneedle.
Figures 4a-d are side cross-sectional views illustrating a preferred method for making hollow microneedles.
:20 Figures Sa-d are side cross-sectional views illustrating a preferred method for making hollow silicon microtubes.
Figures 6a-a are side cross-sectional views illustrating a preferred method for making hollow metal microtub~es.
Figures 7a-d are side cross-sectional views illustrating a preferred method for making tapered metal microneedles.
Figures 8a-d are side cross-sectional views illustrating a method for making tapered microneedies using laser-formed molds.
Figures 9a-f are side cross-sectional views illustrating a second method for making tapered microneedles using laser-formed molds.
Detailed Description Of The Invention 1. Biological Barriers The devices disclosed herein are useful in transport of material into or across biological barriers including the skin (or parts thereof); the blood-brain barrier; mucosal tissue (e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, respiratory); blood vessels; lymphatic vessels; or cell membranes {e.g., for the introduction of material into the interior of a cell or cells). iChe biological barners can be in humans or other types of animals, as well as in plants, insects, or other organisms, including bacteria, yeast, fungi, and embryos.
The microneedle devicE;s can be applied to tissue internally with the aid of a catheter or laparoscope. Far certain applications, such as for drug delivery to an internal LO tissue, the devices can be surgically implanted.
The microneedle device; disclosed herein is typically applied to skin. The stratum corneum is the outer layer, generally between 10 and 50 cells, or between 10 and 20 pm thick. Unlike other tissue in the body, the stratum corneum contains "cells"
(called keratinocytes) filled with bundles of cross-linked keratin and keratohyalin surrounded by an extracellular matrix of lipids. It is this structure that is believed to give skin its barrier properties, which prevents therapeutic transdermal administration of many drugs. Below the stratum corneum is the viable epidermis, which is between 50 and 100 pm thick. The viable epidermis contains no blood vessels, and it exchanges metabolites by diffusion to and from the dermis. Beneath the viable epidermis is the dermis, which is between 1 and ;20 3 mm thick and contains blood vessels, lymphatics, and nerves.
2. The Microneedle Device The microneedle devices disclosed herein include a substrate; one or more microneedles; and, optionally, a reservoir for delivery of drugs or collection of analyte, as well as pump(s), sensor(s), andUor microprocessors) to control the interaction of the foregoing.
a. Substrate The substrate of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites. The substrate includes the base to which the microneedles are attached or integrally formed.
A reservoir may also be attached to the substrate.
b. Microneedle The microneedles of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites.
Preferred materials of construction include pharmaceutical grade stainless steel, gold, titanium, nickel, iron, gold, tin, chromium, copper, alloys of these or other metals, silicon, silicon dioxide, and polymers. lR.epresentative biodegradable polymers include polymers of hydroxy acids such as lactic acid and glycolic acid polylactide, polyglycolide, polylactide-co-glycolide, and copolymers with PEG, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone).
Representative non-biodegradable polymers include polycarbonate, polymethacrylic acid, ethylenevinyl acetate, polytetrafluoroethylene (TEFLONT"'), and polyesters.
Generally, the microneedles should have the mechanical strength to remain intact for delivery of drugs, or serve a;s a conduit for the collection of biological fluid, while being inserted into the skin, while remaining in place for up to a number of days, and while being removed. In embodiments where the microneedles are formed of biodegradable polymers, however, this mechanical requirement is less stringent, since the microneedles or tips thereof can. break off, for example in the skin, and will biodegrade.
Nonetheless, even a biodegradalble microneedle still needs to remain intact at least long enough for the microneedle to serve its intended purpose (e.g., its conduit function).
Therefore, biodegradable microneedles can provide an increased level of safety, as compared to nonbiodegradable .ones. The microneedles should be sterilizable using standard methods.
The microneedles can bc; formed of a porous solid, with or without a sealed coating or exterior portion, or hollow. As used herein, the term "porous"
means having pores or voids throughout at least a portion of the microneedle structure, sufficiently large and sufficiently interconnected to permit passage of fluid and/or solid materials through the microneedle. As used herein, the term "hollow" means having one or more substantially annular bores or channels through the interior of the microneedle structure, having a diameter sufficiently 1<~rge to permit passage of fluid and/or solid materials through the microneedle. The axmular bores may extend throughout all or a portion of the needle in the direction of the tip to the base, extending parallel to the direction of the needle or branching or exiting at a side of the needle, as appropriate. A
solid or porous microneedle can be hollow. One of skill in the art can select the appropriate porosity and/or bore features required for specific applications. For example, one can adjust the pore size or bore diameter to permit passage of the particular material to be transported through the microneedle device.
The microneedles can have straight or tapered shafts. A hollow microneedle that has a substantially uniform diameter, which needle does not taper to a point, is referred to herein as a "microtube." As used herein, the term "microneedle" includes both microtubes and tapered needles unless otherwise indicated. In a preferred embodiment, the diameter of the microneedle; is greatest at the base end of the microneedle and tapers to a point at the end distal the base. The microneedle can also be fabricated to have a shaft that includes both a straight (untapered) portion and a tapered portion.
The microneedles can be formed with shafts that have a circular cross-section in the perpendicular, or the cross-section can be non-circular. For example, the cross-1.5 section of the microneedle can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape. The shaft can have one or more bores. The cross-sectional dimensions typically are between about 10 nm and 1 mm, preferably between 1 micron and microns, and more preferably between 10 and 100 p.m. The outer diameter is typically between about 10 ~m and about 100 pm, and the inner diameter is typically between ~!0 about 3 ~m and about 80 Vim.
The length of the microneedles typically is between about 1 ~m and 1 mm, preferably between 10 microns and 500 microns, and more preferably between 30 and 200 p,m. The length is selected. for the particular application, accounting for both an inserted and uninserted portion. An array of microneedles can include a mixture of 5 microneedles having, for example, various lengths, outer diameters, inner diameters, cross-sectional shapes, and spacings between the microneedles.
The microneedles can be oriented perpendicular or at an angle to the substrate.
Preferably, the microneedles are oriented perpendicular to the substrate so that a larger density of microneedles per unit area of substrate is provided. An array of microneedles 30 can include a mixture of micro:needle orientations, heights, or other parameters.
In a preferred embodiment of the device, the substrate and/or microneedles, as well as other components, are formed from flexible materials to allow the device to fit the contours of the biological barrier, such as the skin, vessel walls, or the eye, to which the device is applied. A flexible device facilitates more consistent penetration during use, since penetration can be limited by deviations in the attachment surface. For example, the surface of human skin is not flat due to dermatoglyphics (i.e. tiny wrinkles) and hair.
c. Reservoir The microneedle device: may include a reservoir in communication with the microneedles. The reservoir can be attached to the substrate by any suitable means. In a l0 preferred embodiment, the reservoir is attached to the back of the substrate {opposite the microneedles) around the periphery, using an adhesive agent (e.g., glue). A
gasket may also be used to facilitate formation of a fluid-tight seal.
In a preferred embodiment, the reservoir contains drug, for delivery through the microneedles. The reservoir may be a hollow vessel, a porous matrix, or a solid form :l5 including drug which is transported therefrom. The reservoir can be formed from a variety of materials that are compatible with the drug or biological fluid contained therein. Preferred materials include natural and synthetic polymers, metals, ceramics, semiconductors, organics, and .composites.
The microneedle device; can include one or a plurality of chambers for storing :ZO materials to be delivered. In th.e embodiment having multiple chambers, each can be in fluid connection with all or a portion of the microneedles of the device array. In one embodiment, at least two chambers are used to separately contain drug (e.g., a lyophilized drug, such as a vaccine) and an administration vehicle (e.g., saline) in order to prevent or minimize degradation during storage. Immediately before use, the contents of the 25 chambers are mixed. Mixing can be triggered by any means, including, for example, mechanical disruption (i.e. puncturing or breaking), changing the porosity, or electrochemical degradation of the walls or membranes separating the chambers.
In another embodiment, a single device is used to deliver different drugs, which are stored separately in different chambers. In this embodiment, the rate of delivery of each drug 30 can be independently controlled.
In a preferred embodiment, the reservoir should be in direct contact with the microneedles and have holes through which drug could exit the reservoir and flow into the interior of hollow or porous microneedles. In another preferred embodiment, the reservoir has holes which permiit the drug to transport out of the reservoir and onto the skin surface. From there, drug :is transported into the skin, either through hollow or porous microneedles, along the sides of solid microneedles, or through pathways created by microneedles in the skin.
d. Transport Control Components The microneedle device also must be capable of transporting material across the barrier at a useful rate. For example, the microneedle device must be capable of delivering drug across the skin ;~t a rate sufficient to be therapeutically useful. The device may include a housing with microelectronics and other micromachined structures to control the rate of delivery either according to a preprogrammed schedule or through active interface with the patient., a healthcare professional, or a biosensor.
The rate can be controlled by manipulating a variety of factors, including the characteristics of the drug formulation to be delivered (e.g., its viscosity, electric charge, and chemical composition); the dimensions o:f each microneedle (e.g., its outer diameter and the area of porous or hollow openings); the number of microneedles in the device; the application of a driving force (e.g., a concentration gradient, a voltage gradient, a pressure gradient); and the use of a valve.
The rate also can be controlled by interposing between the drug in the reservoir and the openings) at the base end of the microneedle polymeric or other materials selected for their diffusion char<~cteristics. For example, the material composition and layer thickness can be manipulated using methods known in the art to vary the rate of diffusion of the drug of interest through the material, thereby controlling the rate at which the drug flows from the reservoir through the microneedle and into the tissue.
Transportation of molecules through the microneedles can be controlled or monitored using, for example, various combinations of valves, pumps, sensors, actuators, and microprocessors. These components can be produced using standard manufacturing or microfabrication techniques. Actuators that may be useful with the microneedle devices disclosed herein include; micropumps, microvalves, and positioners. In a preferred embodiment, a microprocessor is programmed to control a pump or valve, thereby controlling the rate of delivery.
Flow of molecules through the microneedles can occur based on diffusion, capillary action, or can be induced using conventional mechanical pumps or nonmechanical driving forces, such as electroosmosis or electrophoresis, or convection.
For example, in electroosmosis, electrodes are positioned on the biological barrier surface, one or more microneedles, and/or the substrate adjacent the needles, to create a convective flow which carries appositely charged ionic species and/or neutral molecules toward or into the biological barrier. In a preferred embodiment, the microneedle device J! 0 is used in combination with another mechanism that enhances the permeability of the biological barrier, for example by increasing cell uptake or membrane disruption, using electric fields, ultrasound, chemical enhancers, vacuum viruses, pH, heat and/or light.
Passage of the micronec;dles, or drug to be transported via the microneedles, can be manipulated by shaping the microneedle surface, or by selection of the material 1.5 forming the microneedle surface (which could be a coating rather than the microneedle per se). For example, one or more grooves on the outside surface of the microneedles can be used to direct the passage of drug, particularly in a liquid state.
Alternatively, the physical surface properties of the microneedle can be manipulated to either promote or inhibit transport of material along the microneedle surface, such as by controlling ~!0 hydrophilicity or hydrophobicit:y.
The flow of molecules c;an be regulated using a wide range of valves or gates.
These valves can be the type that are selectively and repeatedly opened and closed, or they can be single-use types. For example, in a disposable, single-use drug delivery device, a fracturable barrier or one-way gate may be installed in the device between the ~!5 reservoir and the opening of thc; microneedles. When ready to use, the barrier can be broken or gate opened to permit flow through the microneedles. Other valves or gates used in the microneedle devices can be activated thermally, electrochemically, mechanically, or magnetically 1:a selectively initiate, modulate, or stop the flow of molecules through the needles. In a prefen:ed embodiment, flow is controlled by using a ;40 rate-limiting membrane as a "valve."
The microneedle devices can further include a flowmeter or other means to monitor flow through the micra~needles and to coordinate use of the pumps and valves.
e. Sensors Useful sensors may include sensors of pressure, temperature, chemicals, and/or electro-magnetic fields. Biosensors can be located on the microneedle surface, inside a hollow or porous microneedle, ~or inside a device in communication with the body tissue via the microneedle (solid, hollow, or porous). These microneedle biosensors can include four classes of principal transducers: potentiometric, amperometric, optical, and physiochemical. An amperome:tric sensor monitors currents generated when electrons are exchanged between a biological system and an electrode. Blood glucose sensors frequently are of this type.
The microneedle may function as a conduit for fluids, solutes, electric charge, light, or other materials. In one embodiment, hollow microneedles can be filled with a substance, such as a gel, that has a sensing functionality associated with it.
In an application for sensing based on binding to a substrate or reaction mediated by an enzyme, the substrate or enzyme can be immobilized in the needle interior, which would be especially useful in a porous needle to create an integral needle/sensor.
Wave guides can be incorporated into the microneedle device to direct light to a specific location, or for detection, for example, using means such as a pH dye for color evaluation. Similarly, heat, ele<;tricity, light or other energy forms may be precisely transmitted to directly stimulate, damage, or heal a specific tissue or intermediary {e.g., tattoo remove for dark skinned lpersons), or diagnostic purposes, such as measurement of blood glucose based on IR spectra or by chromatographic means, measuring a color change in the presence of immobilized glucose oxidase in combination with an appropriate substrate.
f. Attachment Features A collar or flange also can be provided with the device, for example, around the periphery of the substrate or the base. It preferably is attached to the device, but alternatively can be formed as an integral part of the substrate, for example by forming microneedles only near the center of an "oversized" substrate. The collar can also emanate from other parts of the device. The collar can provide an interface to attach the microneedle array to the rest ojP the device, and can facilitate handling of the smaller devices.
In a preferred embodiment, the microneedle device includes an adhesive to temporarily secure the device to the surface of the biological barrier. The adhesive can be essentially anywhere on the device to facilitate contact with the biological barrier. For example, the adhesive can be on the surface of the collar (same side as microneedles), on the surface of the substrate between the microneedles (near the base of the microneedles), or a combination thereof.
g. Transdermal Micron.eedle Device :l0 Figure I is a side elevational view of a schematic of a preferred embodiment of the microneedle device inserted into skin. The device 10 includes an upper portion or substrate 11 from which a plurality of microneedles 12 protrude. The height of the upper portion 11 is between about 1 l,~m and 1 cm, and the width of the upper portion is between about 1 mm and 10 em. The upper portion 11 of the device can be solid or hollow, and '.l5 may include multiple compartments. In a preferred embodiment for drug delivery, the upper portion 11 contains one or more drugs to be delivered. It is also preferred that the upper portion include one or more sensors and/or an apparatus (e.g., pump or electrode) to drive (provide/direct the force) transport of the drug or other molecules.
The height (or length) of the microneedles 12 generally is between about 1 ~m 20 and I mm. The diameter and length both affect pain as well as functional properties of the needles. In transdermal apI>lications, the "insertion depth" of the microneedles 12 is preferably less than about 100 lam, more preferably about 30 ~,m, so that insertion of the microneedles 12 into the skin through the stratum corneum 14 does not penetrate past the epidermis 16 into the dermis lg (as described below), thereby avoiding contacting nerves :!5 and reducing the potential for causing pain. In such applications, the actual length of the microneedles may be longer, since the portion of the microneedles distal the tip may not be inserted into the skin; the uninserted length depends on the particular device design and configuration. The actual (overall) height or length of microneedles 12 should be equal to the insertion depth plus the uninserted length.
:10 The diameter of each microneedle 12 generally is between about 10 nm and 1 mm, and preferably leaves a residual hole (following microneedle insertion and withdrawal) of less than about 1 pm, to avoid making a hole which would allow bacteria to enter the penetration wound. The actual microneedle diameter should be larger than 1 p,m, since the hole likely will contract following withdrawal of the microneedle. The diameter of microneedle 12 more preferably is between about 1 ~m and 100 p.m.
Larger diameter and longer microneedles are acceptable, so long as the microneedle can penetrate the biological barrier to the desired depth and the hole remaining in the skin or other tissue following withdrawal of the microneedle is sufficiently small, preferably small enough to exclude bacteriial entry. The microneedles 12 can be solid or porous, and can include one or more bores connected to upper portion 11.
l.0 3. Methods of Making Micro~needle Devices The microneedle devices are made by microfabrication processes, by creating small mechanical structures in :>ilicon, metal, polymer, and other materials.
These microfabrication processes are based on well-established methods used to make integrated circuits, electronic packages and other microelectronic devices, augmented by additional methods used in the field of micromachining. The microneedle devices can have dimensions as small as a few nanometers and can be mass-produced at low per-unit costs.
a. Microfabrication Processes Microfabrication processes that may be used in making the microneedles f,0 disclosed herein include lithography; etching techniques, such as wet chemical, dry, and photoresist removal; thermal oxidation of silicon; electroplating and electroless plating;
diffusion processes, such as boron, phosphorus, arsenic, and antimony diffusion; ion implantation; film deposition, such as evaporation (filament, electron beam, flash, and shadowing and step coverage), sputtering, chemical vapor deposition (CVD), epitaxy 2.5 (vapor phase, liquid phase, and molecular beam), electroplating, screen printing, lamination, stereolithography, laser machining, and laser ablation (including projection ablation). See generally Jaeger, Introduction to Microelectronic Fabrication (Addison-Wesley Publishing Co., Reading MA 1988); Runyan, et al., Semiconductor Integrated Circuit Processing Technology (Addison-Wesley Publishing Co., Reading MA
1990);
3~0 Proceedings of the IEEE Micro Electro Mechanical Systems Conference 1987-1998; Rai-Choudhury, ed., Handbook of Iviicrolithographv. Micromachining &
Microfabrication (SPIE Optical Engineering Press, Bellingham, WA 1997).
The following methods are preferred for making microneedles.
i. electrochemical etching of silicon In this method, electrochemical etching of solid silicon to porous silicon is used to create extremely fine (on the order of 0.01 ~,m) silicon networks which can be used as piercing structures. This method uses electrolytic anodization of silicon in aqueous hydrofluoric acid, potentially in combination with light, to etch channels into the silicon.
By varying the doping concentavation of the silicon wafer to be etched, the electrolytic ).0 potential during etching, the iinc;ident light intensity, and the electrolyte concentration, control over the ultimate pore structure can be achieved. The material not etched (i.e. the silicon remaining) forms the miicroneedles. This method has been used to produce irregular needle-type structures measuring tens of nanometers in width.
ii. plasma etching 1.5 This process uses deep plasma etching of silicon to create microneedles with diameters on the order of 0.1 p.m or larger. Needles are patterned directly using photolithography, rather than indirectly by controlling the voltage (as in electrochemical etching), thus providing greater control over the final microneedle geometry.
In this process, an appropriate masking material (e.g., metal) is deposited onto a silicon wafer substrate and patterned into dots having the diameter of the desired microneedles. The wafer is then subjected to a carefully controlled plasma based on fluorine/oxygen chemistries to etch very deep, high aspect ratio trenches into the silicon.
See, e.g., Jansen, et al., "The Black Silicon Method IV: The Fabrication of Three-Dimensional Structures in Silicon with High Aspect Ratios for Scanning Probe 5 Microscopy and Other Applications," IEEE Proceedings of Micro Electro Mechanical Systems Conference, pp. 88-93 (1995). Those regions protected by the metal mask remain and form the needles. 'This method is further described in Example 1 below.
iii. electroplating In this process, a metal payer is first evaporated onto a planar substrate. A
layer of ~~0 photoresist is then deposited onto the metal to form a patterned mold which leaves an exposed-metal region in the shape of needles. By electroplating onto the exposed regions of the metal seed layer, the mold bounded by photoresist can be filled with electroplated material. Finally, the substrate and photoresist mold are removed, leaving the finilshed microneedle array. The microneedles produced by this process generally have diameters on the order of 1 pm or larger. See, e.g., Frazier, et al., "Two dimensional metallic microelectrode arrays for extracellular stimulation and recording of neurons", IEEE
Proceedings of the Micro Elec~'ro Mechanical Systems Conference, pp. I 95-200 ( 1993).
iv. other processes Another method for forming microneedles made of silicon or other materials is to use microfabrication techniques such as photolithography, plasma etching, or laser :10 ablation to make a mold form (A), transfernng that mold form to other materials using standard mold transfer techniques, such as embossing or injection molding (B), and reproducing the shape of the oziginal mold form (A) using the newly-created mold (B) to yield the final microneedles (C). Alternatively, the creation of the mold form (A) could be skipped and the mold (B) could be microfabricated directly, which could then be used TS to create the final microneedles~ (C).
Another method of fornaing solid silicon microneedles is by using epitaxial growth on silicon substrates, as is utilized by Containerless Research, Inc.
(Evanston, Illinois, USA) for its products.
b. Hollow or Porous Microneedles ~!0 In a preferred embodiment, microneedles are made with pores or other pathways through which material may be transported. The following descriptions outline representative methods for fabricating either porous or hollow microneedles.
i. porous microneedles Rather than having a single, well-defined hole down the length of the needle, ~;5 porous needles are filled with a network of channels or pores which allow conduction of fluid or energy through the needle shaft. It has been shown that by appropriate electrochemical oxidation of silicon, pore arrays with high aspect ratios and a range of different pore size regimes can be formed; these pore regimes are defined as ( I ) microporous regime with average pore dimensions less than 2 nm, (2) mesoporous regime a0 with average pore sizes of betvs~een 2 nm and 50 zun, and (3) macroporous regime with pores greater than SO nm. The mesoporous and macroporous regimes are expected to be most useful for drug delivery. 'Two approaches to porous needles are generally available, either (a) the silicon wafer is first made porous and then etched as described above to form needles or (b) solid microneedles are etched and then rendered porous, for example, by means of electrochemical oxidation, such as by anodization of a silicon substrate in a hydrofluoric acid electrolyte. 7.'he size distribution of the etched porous structure is highly dependent on several variables, including doping kind and illumination conditions, as detailed in Lehmann, "Porou.s Silicon--A New Material for MEMS", IEEE
Proceedings of the Micro Electro Mechanical Systems Conference, pp. 1-6 (1996).
Porous polymer or metallic microneedles can be formed, for example, by micromolding a 1.0 polymer containing a volatilizalble or teachable material, such as a volatile salt, dispersed in the polymer or metal, and thf,n volatilizing or leaching the dispersed material, leaving a porous polymer matrix in the shape of the microneedle.
ii. hollow needles Three-dimensional arrays of hollow rnicroneedles can be fabricated, for example, l 5 using combinations of dry etching processes (Laermer, et al., "Bosch Deep Silicon Etching: Improving Uniformity and Etch Rate for Advanced MEMS Applications,"
Micro Electro Mechanical Systems, Orlando, Fl, USA, (Jan. 17-21, 1999);
Despont et aL, "High-Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photoresist for MEMS", Proc.
of IEEE 10'h Annual InternatiorTal Workshop on MEMS, Nagoya, Japan, pp. S 18-522 (Jan.
2;0 26-30, 1997)); micromold creation in lithographically-defined and/or laser ablated polymers and selective sidewall. electroplating; or direct micromolding techniques using epoxy mold transfers.
One or more distinct and continuous pathways are created through the interior of microneedles. In a preferred embodiment, the microneedle has a single annular pathway 2.5 along the center axis of the microneedle. This pathway can be achieved by initially chemically or physically etching the holes in the material and then etching away microneedles around the hole. .Alternatively, the microneedles and their holes can be made simultaneously or holes can be etched into existing microneedles. As another option, a microneedle form or mold can be made, then coated, and then etched away, ?~0 leaving only the outer coating to form a hollow microneedle. Coatings can be formed either by deposition of a film on by oxidation of the silicon microneedles to a specific thickness, followed by removal of the interior silicon. Also, holes from the backside of the wafer to the underside of the hollow needles can be created using a front-to-backside infrared alignment followed by etching from the backside of the wafer.
a. silicon microneedles S One method for hollow needle fabrication is to replace the solid mask used in the formation of solid needles by a mask that includes a solid shape with one or more interior regions of the solid shape removed. One example is a "donut-shaped" mask.
Using this type of mask, interior regions of the needle are etched simultaneously with their side walls. Due to lateral etching of the inner side walls of the needle, this may not produce sufficiently sharp walls. In that case, two plasma etches may be used, one to form the outer walls of the microneedle (i.e., the 'standard' etch), and one to form the inner hollow core (which is an extremely anisotropic etch, such as in inductively-coupled-plasma "ICP" etch). For example, the I:C;P etch can be used to form the interior region of the needle followed by a second photolithography step and a standard etch to form the outer walls of the microneedle. Figure 2a represents a silicon wafer 82 with a patterned photoresist layer 84 on top of the wafer 82. The wafer 82 is anisotropically etched (Figure 2b) to form a cavity 86 through its entire thickness (Figure 2c). The wafer 82 is then coated with a chromium layer 88 followed by a second photoresist layer 90 patterned so as to cover the cavity 86 and form a circular mask for subsequent etching (Figure 2d).
The wafer 82 is then etched by ;a standard etch to form the outer tapered walls 92 of the microneedle (Figure 2e).
Alternatively, this structure can be achieved by substituting the chromium mask used for the solid microneedles described in Example 1 by a silicon nitride layer 94 on the silicon substrate 95 covered with chromium 96, deposited as shown in Figure 3a and patterned as shown in Figure 3b~. Solid microneedles are then etched as described in Example 1 as shown Figure 3c, the chromium 96 is stripped (Figure 3d), and the silicon 95 is oxidized to form a thin layer of silicon dioxide 97 on all exposed silicon surfaces (Figure 3e). The silicon nitride layer 94 prevents oxidation at the needle tip. The silicon nitride 94 is then stripped (Figure 3f), leaving exposed silicon at the tip of the needle and oxide-covered silicon 97 everywhere else. The needle is then exposed to an ICP
plasma which selectively etches the inr.~er sidewalls of the silicon 95 in a highly anisotropic manner to form the interior hole of the needle (Figure 3g).
Another method uses the solid silicon needles described previously as 'forts' around which the actual needle structures are deposited. After deposition, the forms are etched away, yielding the hollow structures. Silica needles or metal needles can be formed using different methods. Silica needles can be formed by creating needle structures similar to the ICP neE:dles described above prior to the oxidation described above. The wafers are then oxidized to a controlled thickness, forming a layer on the shaft of the needle form which will eventually become the hollow microneedle.
The silicon nitride is then stripped and the silicon core selectively etched away (e.g., in a wet alkaline solution) to form a hollow silica microneedle.
In a preferred embodimc;nt, an array of hollow silicon microtubes is made using deep reactive ion etching combined with a modified black silicon process in a conventional reactive ion etches, as described in Example 3 below. First, arrays of circular holes are patterned through photoresist into Si02 , such as on a silicon wafer.
Then the silicon can be etched using deep reactive ion etching (DRIE) in an inductively coupled plasma (ICP) reactor to etch deep vertical holes. The photoresist was then removed. Next, a second photolithography step patterns the remaining Si02 layer into circles concentric to the holes, leaving ring shaped oxide masks surrounding the holes.
The photoresist is then removedl and the silicon wafer again deep silicon etched, such that the holes are etched completely through the wafer (inside the Si02 ring) and simultaneously the silicon is etched around the Si02 ring leaving a cylinder.
This latter process can be varied to produce hollow, tapered microneedles.
After an array of holes is fabricated as described above, the photoresist and Si02 layers are replaced with conformal DC sputtered chromium rings. The second ICP etch is replaced with a SF6/02 plasma etch in a reactive ion etches (RIE), which results in positively sloping outer sidewalls. Henry, et al., "Micromachined Needles for the Transdermal Delivery of Drugs," Micro Electro Mechanical Systems, Heidelberg, Germany, pp.
498 (Jan. 26-29, 1998).
b. metal ,mieroneedles Metal needles can be foamed by physical vapor deposition of appropriate metal layers on solid needle forms, which can be made of silicon using the techniques described above, or which can be formed using other standard mold techniques such as embossing or injection molding. The metals are selectively removed from the tips of the needles using electropolishing techniques, in which an applied anodic potential in an electrolytic solution will cause dissolution of metals more rapidly at sharp points, due to concentration of electric field lines at the sharp points. Once the underlying silicon needle forms have been exposed at the tips, the silicon is selectively etched away to form hollow metallic needle structurca. This process could also be used to make hollow needles made from other materials by depositing a material other than metal on the needle forms and following the procedure described above.
A preferred method of fabricating hollow metal microneedles utilizes micromold plating techniques, which are dfacribed as follows and in Examples 4 and S. In a method for making metal microtubes, which does not require dry silicon etching, a photo-defined mold first is first produced, for .example, by spin casting a thick layer, typically 1 SO lun, of an epoxy (e.g., SU-8) onto a substrate that has been coated with a thin sacrificial layer, typically about 10 to 50 nm. .A~xays of cylindrical holes are then photolithographieally defined through the epoxy layer, which typically is about 150 p,m thick.
(Despont, et al., "High-Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photoresist fox MEMS,''' Proc.
of IEEE 10'h Annual International Workshop on MEMS, Nagoya, Japan, pp. 518-522 (Jan.
26-30, 1997)). The diameter of these cylindrical holes defines the outer diameter of the tubes. The upper surface of the substrate, the sacrificial layer, is then partially removed at the bottom of the cylindrical holes in the photoresist. The exact method chosen depends on the choice of substrate. For example, the process has been successfully performed on silicon and glass substrates (in which the upper surface is etched using isotropic wet or dry etching techniques) and copper-clad printed wiring board substrates. In the latter case, the copper laminate is selectively removed using wet etching. Then a seed layer, such as Ti/Cu/Ti (e.g., 30 nm/21)0 nm/30 nm), is conformally DC sputter-deposited onto the upper surface of the epoxy mold and onto the sidewalls of the cylindrical holes. The seed layer should be electrically isolated from the substrate. Subsequently, one or more electroplatable metals or alloys, such as Ni, NiFe, Au, Cu, or Ti, are electroplated onto the seed layer. The surrounding epoxy is then removed, leaving microtubes which each have an interior annular hole that extends through the base metal supporting the tubes.
The rate and duration of electra~plating is controlled in order to define the wall thickness and inner diameter of the micro~tubes. In one embodiment, this method was used to produce microtubes having a hc;ight of between about 150 and 250 pm, an outer diameter of between about 40 and 120 ~Cm, and an inner diameter of between about 30 and 110 ~m (i.e., having a wall thickness of 10 p,m). In a typical array, the microtubes have a tube center-to-center spacing of about 150 p,m, but can vary depending on the desired needle l.0 density.
A variation of this method is preferred for forming tapered microneedles. .As described above, photolithography yields holes in the epoxy which have vertical sidewalls, such that the resulting shafts of the microneedles are straight, not tapered. This vertical sidewall limitation can be overcome by molding a preexisting 3D
structure, i.e., a mold-insert. The subsequent removal of the mold-insert leaves a mold which can be surface plated similarly to the holes produced by photolithography described above.
Alternatively, non-vertical sidewalk can be produced directly in the polymeric mold into which electroplating will take place. For example, conventional photoresists known in the art can be exposed and developed in such as way as to have the surface 2;0 immediately adjacent to the mask be wider than the other surface.
Specialized greyscale photoresists in combination with greyscale masks can accomplish the same effect. Laser-ablated molds can also be made: with tapered sidewalk, e.g., by optical adjustment of the beam (in the case of serial hole fabrication) or of the reticle or mold during ablation (in the case of projection ablation).
Z;5 To form hollow tapered microneedles, the mold-insert is an array of solid silicon microneedles, formed as described in Henry, et al., "Micromachined Needles for the Transdermal Delivery of Drugs;'" Micro Electro Mechanical Systems, Heidelberg, Germany, Jan. 26-29, pp. 494-498 (1998). First, a layer of a material, such as an epoxy (e.g., SU-8 or a polydimethylsil.oxane ("PDMS")), is spin cast onto the array of silicon ?~0 microneedles to completely blanket the entire array. 'the epoxy settles during pre-bake to create a planar surface above the silicon needle tips; the material is then fully pre-baked, photolithographically cross-linls;ed, and post-baked.
The upper surface of the: epoxy is then etched away, for example with an plasma, until the needle tips are exposed, preferably leaving between about 1 and S p,m of tip protruding from the epoxy. 'The silicon is then selectively removed, for example by using a SF6 plasma or a HN03/13F solution. The remaining epoxy micromold is the negative of the microneedles and has a small diameter hole where the tip of the microneedle formerly protruded.
After the removal of the silicon, a seed layer, such as Ti-Cu-Ti, is conformally sputter-deposited onto the epoxy micromold. Following the same process sequence described for hollow metal microtubes, one or more electroplatable metals or alloys, such as Ni, NiFe, Au, or Cu, are electroplated onto the seed layer. Finally, the epoxy is removed, for example by using .an 02/CHF3 plasma, leaving an array of hollow metal microneedles. An advantage of using PDMS in this application is that the micromold can be physically removed from the silicon mold insert by mechanical means, such as peeling, without damaging the silicon mold insert, thus allowing the silicon mold insert to be reused. Furthermore, the electroplated microneedles can be removed from the PDMS
mold by mechanical means, for example by peeling, thereby allowing the PDMS to also be reused. In a preferred embodliment, this method is used to produce microneedles 2'0 having a height of between about 150 and 250 p,m, an outer diameter of between about 40 and 120 ~tm, and an inner diameter of between about 50 and 100 p,m. In a typical array, the microtubes have a tube centc,r-to-center spacing of about 150 Vim, but can vary depending on the desired needle density. The microneedles are 150 ~m in height with a base diameter of $0 p,m, a tip di,~neter of 10 p,m, and a needle-to-needle spacing of 1 SO
2.5 pm.
c. silicon dioxide microneedles Hollow microneedles formed of silicon dioxide can be made by oxidizing the surface of the silicon microneedle forms (as described above), rather than depositing a metal and then etching away the solid needle forms to leave the hollow silicon dioxide 30 structures. This method is illustrated in Figures 4a-4d. Figure 4a shows an array 24 of needle forms 26 with masks 28 on their tips. In Figure 4b, the needle forms 26 have been coated with a layer 30 of metal, silicon dioxide or other material. Figure 4c shows the coated needle forms 26 with the: masks 28 removed. Finally, in Figure 4d, the needle forms 26 have been etched away, leaving hollow needles 30 made of metal, silicor<
dioxide, or other materials.
In one embodiment, hollow, porous, or solid microneedles are provided with longitudinal grooves or other modifications to the exterior surface of the microneedles.
Grooves, for example, should be useful in directing the flow of molecules along the outside of microneedles.
d. op Iyme~r microneedles In a preferred method, polymeric microneedles are made using microfabricated molds. For example, the epoxy molds can be made as described above and injection molding techniques can be appliied to form the microneedles in the molds (Weber, et al., "Micromolding - a powerful tool for the large scale production of precise microstructures", Proc. SPIE - International Soc. Optical Engineer. 2879, 156-167 (1996);
Schift, et al., "Fabrication of replicated high precision insert elements for micro-optical bench arrangements" Proc. SPIN - International Soc. Optical Engineer. 3513, (1998). These micromolding techniques are preferred over other techniques described herein, since they can provide relatively less expensive replication, i.e.
lower cost of mass production. In a preferred embodiment, the polymer is biodegradable.
2~D 4. Microneedle Device Applications The device may be used for single or multiple uses for rapid transport across a biological barrier or may be left in place for longer times (e.g., hours or days) for long-term transport of molecules. Depending on the dimensions of the device, the application site, and the route in which the device is introduced into (or onto) the biological barrier, 2.5 the device may be used to introdluce or remove molecules at specific locations.
As discussed above, Figure 1 shows a side elevational view of a schematic of a preferred embodiment of the mi~,roneedle device 10 in a transdermal application. The device 10 is applied to the skin such that the microneedles 12 penetrate through the stratum corneum and enter the viable epidermis so that the tip of the microneedle at least 3~D penetrates into the viable epidermis. In a preferred embodiment, drug molecules in a reservoir within the upper portion 11 flow through or around the microneedles and into the viable epidermis, where the drug molecules then diffuse into the dermis for local treatment or for transport through the body.
To control the transport of material out of or into the device through the microneedles, a variety of forcea or mechanisms can be employed. These include S pressure gradients, concentration gradients, electricity, ultrasound, receptor binding, heat, chemicals, and chemical reactions. Mechanical or other gates in conjunction with the forces and mechanisms describE:d above can be used to selectively control transport of the material.
In particular embodiments, the device should be "user-friendly." For example, in some transdermal applications, affixing the device to the skin should be relatively simple, and not require special skills. This embodiment of a microneedle may include an array of microneedles attached to a housing containing drug in an internal reservoir, wherein the housing has a bioadhesive coating around the microneedles. The patient can remove a peel-away backing to expose an adhesive coating, and then press the device onto a clean IS part of the skin, leaving it to administer drug over the course of, for example, several days.
a. Drug Delivery Essentially any drug or other bioactive agents can be delivered using these devices. Drugs can be proteins, enzymes, polysaccharides, polynucleotide molecules, and synthetic organic and inorganic compounds. Representative agents include anti-infectives, hormones, such as insulin, growth regulators, drugs regulating cardiac action or blood flow, and drugs for pain control. The drug can be for local treatment or for regional or systemic therapy. The following are representative examples, and disorders they are used to treat:
Calcitonin, osteoporosis; Enoxaprin, anticoagulant; Etanercept, rheumatoid arthritis; Erythropoietin, anemia; Fentanyl, postoperative and chronic pain;
Filgrastin, low white blood cells from chemotherapy; Heparin, anticoagulant; Insulin, human, diabetes;
Interferon Beta 1 a, multiple sclerosis; Lidocaine, local anesthesia;
Somatropin, growth hormone; and Sumatriptan, migraine headaches.
In this way, many drugs can be delivered at a variety of therapeutic rates.
The rate can be controlled by varying a number of design factors, including the outer diameter of the microneedle, the number and size of pores or channels in each microneedle, the number of microneedles in an array, the magnitude and frequency of application of the force driving the drug through the microneedle and/or the holes created by the microneedles. For example, devices designed to deliver drug at different rates might have more microneedles for more rapid delivery and fewer microneedles for less rapid delivery. As another example, a device designed to deliver drug at a variable rate could vary the driving force (e.g., preasure gradient controlled by a pump) for transport according to a schedule which 'was pre-programmed or controlled by, for example, the user or his doctor. The devices can be affixed to the skin or other tissue to deliver drugs :LO continuously or intermittently, for durations ranging from a few seconds to several hours or days.
One of skill in the art can measure the rate of drug delivery for particular microneedle devices using in mstro and in vivo methods known in the art. For example, to measure the rate of transdermal drug delivery, human cadaver skin mounted on standard :l5 diffusion chambers can be usedl to predict actual rates. See Hadgraft &
Guy, eds., Transdermal Drug Delivery: Developmental Issues and Research Initiatives (Marcel Dekker, New York 1989); Bronaugh & Maibach, Percutaneous Absorption, Mechanisms--Methodol~;,v--Drug Delivery (Marcel Dekker, New York 1989). After filling the compartment on the dermis side of the diffusion chamber with saline, a microneedle array :!0 is inserted into the stratum corneum; a drug solution is placed in the reservoir of the microneedle device; and samples of the saline solution are taken over time and assayed to determine the rates of drug transport.
In an alternate embodiment, biodegradable or non-biodegradable microneedles can be used as the entire drug delivery device, where biodegradable microneedles are a :!5 preferred embodiment. For ex~unple, the microneedles may be formed of a biodegradable polymer containing a dispersion of an active agent for local or systemic delivery. The agent could be released over tune, according to a profile determined by the composition and geometry of the microneedles, the concentration of the drug and other factors. In this way, the drug reservoir is within the matrix of one or more of the microneedles.
;10 In another alternate embodiment, these microneedles may be purposefully sheared off from the substrate after penetrating the biological barrier. In this way, a portion of the microneedles would remain within or on the other side of the biological barrier and a portion of the microneedles and their substrate would be removed from the biological barner. In the case of skin, this could involve inserting an array into the skin, manually or otherwise breaking off the microneedles tips and then remove the base of the microneedles. The portion of the microneedles which remains in the skin or in or across another biological barrier could then release drug over time according to a profile determined by the composition and geometry of the microneedles, the concentration of the drug and other factors. In a~ preferred embodiment, the microneedles are made of a biodegradable polymer. The release of drug from the biodegradable microneedle tips can :l0 be controlled by the rate of polymer degradation. Microneedle tips can release drugs for local or systemic effect, or othc;r agents, such as perfume, insect repellent and sun block.
Microneedle shape and content can be designed to control the breakage of microneedles. For example, a notch can be introduced into microneedles either at the time of fabrication or as a subsequent step. In this way, microneedles would :l5 preferentially break at the site of the notch. Moreover, the size and shape of the portion of microneedles which break off c;an be controlled not only for specific drug release patterns, but also for specific interactions with cells in the body. For example, objects of a few microns in size are known to be taken up by macrophages. The portions of microneedles that break off carp be controlled to be bigger or smaller than that to prevent :'0 uptake by macrophages or can be that size to promote uptake by macrophages, which can be desirable for delivery of vaccines.
b. Dia nostic Sensing of Body Fluids (Biosensors~
One embodiment of the devices described herein may be used to remove material from the body across a biological barrier, i.e. for minimally invasive diagnostic sensing.
5 For example, fluids can be transported from interstitial fluid in a tissue into a reservoir in the upper portion of the device.. The fluid can then be assayed while in the reservoir or the fluid can be removed from the reservoir to be assayed, for diagnostic or other purposes. For example, interstitial fluids can be removed from the epidermis across the stratum corneum to assay for glucose concentration, which should be useful in aiding :30 diabetics in determining their required insulin dose. Other substances or properties that would be desirable to detect ine:lude lactate (important for athletes), oxygen, pH, alcohol, tobacco metabolites, and illegal drugs (important for both medical diagnosis and law enforcement).
The sensing device can be in or attached to one or more microneedles, or in a housing adapted to the substrate. Sensing information or signals can be transferred optically (e.g., refractive index) or electrically (e.g., measuring changes in electrical impedance, resistance, current, voltage, or combination thereof). For example, it may be useful to measure a change as a function of change in resistance of tissue to an electrical current or voltage, or a change in response to channel binding or other criteria (such as an optical change) wherein different resistances are calibrated to signal that more or less :l0 flow of drug is needed, or that delivery has been completed.
In one embodiment, onE: or more microneedle devices can be used for (1) withdrawal of interstitial fluid, (2) assay of the fluid, and/or (3) delivery of the appropriate amount of a therapeutic agent based on the results of the assay, either automatically or with human intervention. For example, a sensor delivery system may be :l5 combined to form, for example, a system which withdraws bodily fluid, measures its glucose content, and delivers a~i appropriate amount of insulin. The sensing or delivery step also can be performed using conventional techniques, which would be integrated into use of the microneedle device. For example, the microneedle device could be used to withdraw and assay glucose, arid a conventional syringe and needle used to administer the :?0 insulin, or vice versa.
In an alternate embodiment, microneedles may be purposefully sheared off from the substrate after penetrating tike biological barrier, as described above.
The portion of the microneedles which remain within or on the other side of the biological barrier could contain one or more biosensors. For example, the sensor could change color as its output.
5 For microneedles sheared off in the skin, this color change could be observed through the skin by visual inspection or with the aid of an optical apparatus.
Other than transport of drugs and biological molecules, the microneedles rnay be used to transmit or transfer other materials and energy forms, such as light, electricity, heat, or pressure. The microneedles, for example, could be used to direct light to specific ;30 locations within the body, in order that the light can directly act on a tissue or on an intermediary, such as light-sen:>itive molecules in photodynamic therapy. The microneedles can also be used for aerosolization or delivery for example directly to a mucosal surface in the nasal or buccal regions or to the pulmonary system.
The microneedle devices disclosed herein also should be useful for controlling transport across tissues other than skin. For example, microneedles can be inserted into the eye across, for example, conjunctiva, sclera, and/or cornea, to facilitate delivery of drugs into the eye. Similarly, microneedles inserted into the eye can facilitate transport of fluid out of the eye, which may be of benefit for treatment of glaucoma.
Microneedles may also be inserted into the bu~ccal (oral), nasal, vaginal, or other accessible mucosa to facilitate transport into, out of, or across those tissues. For example, a drug may be l.0 delivered across the buccal muc;osa for local treatment in the mouth or for systemic uptake and delivery. As another example, microneedle devices may be used internally within the body on, for example, the lining of the gastrointestinal tract to facilitate uptake of orally-ingested drugs or the lining of blood vessels to facilitate penetration of drugs into the vessel wall. For examfde, cardiovascular applications include using microneedle l.5 devices to facilitate vessel distension or immobilization, similarly to a stmt, wherein the microneedles/substrate can function as a "staple-like" device to penetrate into different tissue segments and hold their relative positions for a period of time to permit tissue regeneration. This application could be particularly useful with biodegradable devices.
These uses may involve invasive procedures to introduce the microneedle devices into the ~:0 body or could involve swallowing, inhaling, injecting or otherwise introducing the devices in a non-invasive or minimally-invasive manner.
The present invention will be further understood with reference to the following non-limiting examples.
Example 1: Fabrication of Sa~lid Silicon Microneedles 2:5 A chromium masking miaterial was deposited onto silicon wafers and patterned into dots having a diameter approximately equal to the base of the desired microneedles.
The wafers were then loaded into a reactive ion etcher and subjected to a carefully controlled plasma based on fluorine/oxygen chemistries to etch very deep, high aspect ratio valleys into the silicon. Tlhose regions protected by the metal mask remain and form ?~0 the microneedles.
<100>-oriented, prime grade, 450-550 ~m thick, 10-15 S2-cm silicon wafers (Nova Electronic Materials Tnc;., Richardson, TX) were used as the starting material. The wafers were cleaned in a solutiion of 5 parts by volume deionized water, 1 part 30%
hydrogen peroxide, and 1 part 30% ammonium hydroxide (J.T. Baker, Phillipsburg, NJ) at approximately 80°C for 15 minutes, and then dried in an oven (Blue M
Electric, Watertown, WI) at 150°C for 10 minutes. Approximately 1000 A of chromium (Mat-Vac Technology, Flagler Beach, FL) was deposited onto the wafers using a DC-sputterer (601 Sputtering System, CVC Products, Rochester, NY). The chromium layer was patterned into 20 by 20 arrays of 80 pm .diameter dots with 150 p,m center-to-center spacing using the lithographic process described below.
A layer of photosensitive material (1827 photoresist, Shipley, Marlborough, MA) was deposited onto the chromium layer covering the silicon wafers. A standard lithographic mask (Telic, Santa Monica, CA) bearing the appropriate dot array pattern was positioned on top of the photoresist layer. The wafer and photoresist were then exposed to ultraviolet (UV) light through the mask by means of an optical mask aligner (Hybralign Series 500, Optical Associates, Inc., Milpitas, CA). The exposed photoresist was removed by soaking the wafers in a liquid developer (354 developer, Shipley, Marlborough, MA) leaving the: desired dot array of photoresist on the chromium layer.
Subsequently, the wafers were dipped into a chromium etchant (CR-75; Cyanteck:
Fremont, CA), which etched the chromium that had been exposed during the photolithography step, leaving dot arrays of chromium (covered with photoresist) on the surface of the silicon wafer. The photoresist still present on the chromium dots formed the masks needed for fabrication of the microneedles, described below.
The microneedles were fabricated using a reactive ion etching techniques based .25 on the Black Silicon Method developed at the University of Twente. The patterned wafers were etched in a reactive ion etcher (700 series wafer/batch Plasma Processing System, Plasma Therm, St. Petersburg, FL) with means for ensuring good thermal contact between the wafers and the underlying platen (Apiezon N, K.J. Lesker, Clairton, PA).
The wafers were etched using the following gases and conditions: SF6 (20 standard cubic centimeters per minute) and O > ( 15 standard cubic centimeters per minute) at a pressure of 150 mTorr and a power of 150 W for a run time of approximately 250 minutes.
These conditions caused both deep vertical etching and slight lateral underetching.
By controlling the ratio of flow rates of the SF6 and 02 gases used to form the plasma, the aspect ratio of the microneedles could be adjusted. The regions protected by the chromium masks remained and formed the microneedles. Etching was allowed to proceed until the masks fell off' due to underetching, resulting in an array of sharp silicon spikes.
Example 2: Transdermal Transport Using Solid Microneedles To determine if microfa.bricated microneedles could be used to enhance transdermal drug delivery, axra;ys of microneedles were made using a deep plasma etching J.0 technique. Their ability to penc;trate human skin without breaking was tested and the resulting changes in transderma~l transport were measured.
Arrays of microneedles were fabricated having extremely sharp tips (radius of curvature less than 1 pm), and are approximately 150 pm long. Because the skin surface is not flat due to dermatoglyphics and hair, the full length of these microneedles will not l.5 penetrate the skin. All experiments were performed at room temperature (232°C).
The ability of the microneedles to pierce skin without breaking was then tested.
Insertion of the arrays into skin required only gentle pushing. Inspection by light and electron microscopy showed that more than 95% of microneedles within an array pierced across the stratum corneum of the epidermis samples. Moreover, essentially all of the ~;0 microneedles that penetrated the epidermis remained intact. On those very few which broke, only the top 5-10 p,m wa.s damaged. Microneedle arrays could also be removed without difficulty or additional damage, as well as re-inserted into skin multiple times.
To quantitatively assess the ability of microneedles to increase transdermal transport, calcein permeability of human epidermis with and without inserted microneedle 2;5 arrays was measured. Calcein crosses skin very poorly under normal circumstances and therefore represents an especially difficult compound to deliver. As expected, passive permeability of calcein across unaltered skin was very low, indicating that the epidermis samples were intact.
Insertion of microneedlc;s into skin was capable of dramatically increasing ?~0 permeability to calcein. When microneedles were inserted and left embedded in the skin, calcein permeability was increased by more than 1000-fold. Insertion of microneedles for s, followed by their removal, yielded an almost 10,000-fold increase. Finally, insertion of a microneedle array for 1 h, followed by its removal, increased skin permeability by about 25,000-i:old. Permeabilities for skin with microneedles inserted and then removed are higher tr~an for skin with microneedles remaining embedded 5 probably because the micronee;dles themselves or the silicon plate supporting the array may block access to the micro:ecopic holes created in the skin. Light microscopy showed that the holes which remained :in the skin after microneedles were removed were approximately 1 ~m in size.
To confirm in vitro experiments which showed that skin permeability can be 10 significantly increased by microneedles, studies were conducted with human volunteers.
They indicated that microneedl',es could be easily inserted into the skin of the forearm or hand. Moreover, insertion of nnicroneedle arrays was never reported to be painful, but sometimes elicited a mild "we~~ring" sensation described as a weak pressure or the feeling of a piece of tape affixed to the: skin. Although transport experiments were not performed in vivo, skin electrical resistance was measured before and after microneedle insertion.
Microneedles caused a 50-fold drop in skin resistance, a drop similar to that caused by the insertion of a 30-gauge "macroneedle." Inspection of the site immediately after microneedle insertion showed no holes visible by light microscopy. No erythema, edema, or other reaction to microneedles was observed over the hours and days which followed.
:20 This indicates that microneedle; arrays can permeabilize skin in human subjects in a non-painful and safe manner.
Example 3: Fabrication of Silicon Microtubes Three-dimensional arrays of rnicrotubes were fabricated from silicon, using deep reactive ion etching combined with a modified black silicon process in a conventional :25 reactive ion etcher. The fabrication process is illustrated in Figures Sa-d. First, arrays of 40 pm diameter circular holes 32 were patterned through photoresist 34 into a 1 pm thick Si02 layer 36 an a two inch siliicon wafer 38 (Figure Sa). The wafer 38 was then etched using deep reactive ion etching; (DRIE) (Laermer, et al., "Bosch Deep Silicon Etching:
Improving Uniformity and Etclh Rate for Advanced MEMS Applications," Micro Electro 30 Mechanical Systems, Orlando, Florida, USA (Jan. 17-21, 1999)). in an inductively coupled plasma (ICP) reactor to etch deep vertical holes 40. The deep silicon etch was stopped after.the holes 40 are approximately 200 ~m deep into the silicon substrate 38 (Figure Sb) and the photoresist 34 was removed. A second photolithography step patterned the remaining Si02 layer 36 into circles concentric to the holes, thus leaving ring shaped oxide masks 34 swTOUnding the holes (Figure Sc). The photoresist 34 was then removed and the wafer 38 was again deep silicon etched, while simultaneously the holes 40 were etched completely through the wafer 38 (inside the SiOZ ring) and the silicon was etched around the Si02 ring 38 leaving a cylinder 42 (Figure Sd).
The resulting tubes were 150 pm in height, with an outer diameter of 80 Vim, an inner diameter of 40 pm, and a tube center-to-center spacing of 300 N.m.
l.0 Example 4: Micromold Fabrication of Metal Microtubes Hollow metal microtubes were prepared without dry silicon etching, using a thick, photo-defined mold of epoxy. 'The sequences are illustrated in Figures 6a-e.
First, a thick layer of SU-8 epoxy 44 was spin cast onto a silicon or glass substrate 46 that had been coated with 30 nm of titanium 48, the sacrificial layer. Arrays of cylindrical holes 49 l.5 were then photolithographically defined through an epoxy layer 44, typically 150 ~m thick (Figure 6a). The sacrificial layer then was partially removed using a wet etching solution containing hydrofluoric acid and water at the bottom of the cylindrical holes in the SU-8 photoresist 46 (Figure: 6b). A seed layer of Ti/Cu/Ti (30 nm/200 nm/30 nm) 39 was then conformally DC sputter-deposited onto the upper surface of the epoxy mold and 20 onto the sidewalls of the cylindrical holes 49 (Figure 6c). As shown in Figure 6c, the seed layer 39 was electrically isolated from the substrate. Subsequently, NiFe was electroplated onto the seed layer 39 (Figure 6d), the epoxy 44 was removed from the substrate, and the surrounding epoxy 44 was removed (Figure 6e). The resulting microtubes are 200 pm in height with an outer diameter of 80 Vim, an inner diameter of 60 2.5 pm, and a tube center-to-center spacing of 150 p,m. T'he holes in the interior of the microtubes protrude through the base metal supporting the tubes.
Example 5: Micromold Fabrication of Tapered Microneedles A micromold having tapered walls was fabricated by molding a preexisting 3-D
array of microneedles, i.e. the mold-insert, and subsequently removing the mold insert.
?'~0 The micromold was then surface plated in a manner similar to that for the microtubes described in Example 4. The fabrication sequence is illustrated in Figures 7a-7d.
First, an array of solid silicon microneedles 50 were prepared as described in Henry, et al., "Micromachined Needles for the Transdermal Delivery of Drugs,"
Micro Electro Mechanical Systems, Hfeidelberg, Germany, Jan. 26-29, pp. 494-498 (1998).
Then, a layer of epoxy 52 (SU-8) was spin cast onto the microneedle array to completely blanket the array (Figure 7a). 'Che epoxy 52 settled during pre-bake to create a planar surface above the tips of the miicroneedles 50. The epoxy 52 was then fully pre-baked, photolithographically cross-linlked, and post-baked.
Then, the upper surface of the epoxy 52 was etched away using an O2/CHF3 plasma until approximately 1 to 2 p,m of the needle tips 54 were exposed, protruding from a0 the epoxy 52 (Figure 7b). The silicon was then selectively removed by using a SF6 plasma (Figure 7c). The remaining epoxy mold 52 provided a negative of the microneedles with a small diameter hole where the tip of the silicon needle protruded.
After the removal of the silicon, a seed layer of Ti-Cu-Ti 54 was conformally sputter-deposited onto the top and sidewalk of the epoxy micromold 52. Following the same :l5 process sequence as described iin Example 4, NiFe was then electroplated onto the seed layer 54 (Figure 7c). Finally, tlhe epoxy was removed using an Oz/CHF3 plasma, leaving a 20 x 20 array of NiFe hollow metal microneedles 54 (Figure 7d). The microneedles 54 were 1 SO p.m in height with a base diameter of 80 p,m, a tip diameter of 10 Vim, and a needle-to-needle spacing of 151) pm.
20 Micromold-based microneedles also have been successfully manufactured using a process in which the epoxy mold material was replaced with PDMS. In this case, it was possible to remove the mold from the mold insert, as well as the microneedles from the mold, using only physical techniques such as peeling. This approach advantageously requires no dry etching and allows one to reuse both the mold and the mold insert.
25 Example 6: Micromold Fabrication of Tapered Microneedles Using Laser-Formed Molds A micromold having tapered walls was fabricated by use of laser ablation techniques, as shown in Figurea 8a-d. A laser-ablatable polymer sheet 60 such as KAPTONTM polyimide approximately 150 microns in thickness was optionally laminated ;30 to a thin (10-30 micron) metal sheet 62 such as titanium (Figure 8a). A
tapered hole 64 was formed in the metal/polymer laminate 60/62 using a laser technique such as excimer WO 99/64580 PC'T/US99/13226 laser ablation,(Figure 8b). The entry hole of the laser spot was on the metal side 62, and a through hole was made through. both the metal sheet and the polymer film. The through hole 64 was tapered in combination with either defocusing or appropriate substrate motion to create a taper such that the wide end of the hole 64 (typically 40-50 microns) was on the metal side 62 and the narrow end of the hole 64 (typically 10-20 microns) was on the polymer 60 side. A thin layer of metal 66, e.g. titanium, of thickness 0.1 micron was then deposited, e.g., using a sputter-deposition technique, in such a way that the metal 66 deposited on the metal. film side and coated the polymer sidewalls, but did not coat the polymer 60 side of the laminate (Figure 8c). Electrodeposition of metal 68, e.g., gold, to a thickness of 1 to 5 microns was then performed on the titanium-coated metal surface 66, and polymer sidewalls curved section of 60 next to 64. Finally, the polymer 60 was removed, using e.g. an oxygen plasma, to form the completed microneedles (Figure 8d).
Alternate polymer removal methods, such as thermal, solvent, aqueous, or photo-degradation followed by solvent or aqueous removal, are also possible if the polymer material is chosen appropriately (e.g., a photoresist resin).
Example 7: Formation of Mi~.roneedles by Embossing Formation of a micronee;dle by embossing is shown in Figures 9a-9f. A
polymeric layer 70 (Figure 9a) is embossed by a solid microneedle or microneedle array 72 (F figure 9b). The array 72 is removed (Figure 9c), and the layer 70 is etched from the non-embossed side 74 until the embossed cavity 76 is exposed (Figure 9d). A
metallic layer 78 is then deposited on the embossed side and the sidewalls, but not on the non-embossed side 74 (Figure 9e). This layer '78 is optionally thickened by electrodeposition of an additional metal layer 80 on top of it (Figure 9e). The polymer layer 70 is then removed to form the microneedles 78/80 (Figure 9f).
Example 8: Transdermal Application of Hollow Microneedles The bore of hollow microneedles must provide fluid flow with minimal clogging in order to be suitable to transport material, such as in transdermal drug delivery.
Therefore, microneedles and microtubes were evaluated to determine their suitability for these functions.
Hollow metal and silicon microneedles, produced as described in Examples 3-5, were inserted through human skin epidermis with no apparent clogging of the needle bores. Scanning electron microscopy of a hollow metal (NiFe) microneedle penetrating up through the underside of hurnan epidermis showed the microneedle remains intact, with the tip free of debris. Simiilarly, silicon microneedles, metal microneedles, and metal microtubes were successfully ir.~serted through human skin. Also, the hollow microneedles were shown to permit the flow of water through their bores.
Example 9: Drug Transporit Through Microneedles Inserted Into Skin Studies were performed with solid and hollow microneedles to demonstrate transport of molecules and fluidls. As shown in Table 1, transport of a number of different compounds across skin is possible using microneedles. These studies were performed using either solid silicon microneedles or using hollow silicon microneedles made by methods described in this patent. Transport was measured across human cadaver epidermis in vitro using Franz dliffusion chambers at 37 °C using methods described in S.
Henry, D. McAllister, M.G. Allen, and M.R. Prausnitz, "Microfabricated microneedles:
A novel method to increase transdermal drug delivery" J. Pharm. Sci. 87: 922-25 (1998).
The transdermal delivery of calcein, insulin, bovine serum albumin and nanoparticles was measured. Delivery refers to the ability to transport these compounds from the stratum corneum side of the epidermis to the viable epidermis side.
This is the direction of transport associated. with delivering drugs into the body.
Removal of calcein was also measured. Removal refers to the ability to transport calcein from the viable epidermis side of the epidermis to the stratum corneum side. This is the direction of transport associated with removing from the body compounds found in the body, such as glucose.
In all cases shown in Talble 1, transport of these compounds across skin occurred at levels below our detection Iinait when no needles were inserted into the skin. Intact skin provides an excellent barrier to transport of these compounds. In all cases examined, when solid microneedles were inserted into the skin and left in place, large skin permeabilities were measured, indicating that the microneedles had created pathways for transport across the skin. Furthermore, in all cases, when solid microneedles were inserted into the skin and then removed, even greater skin permeabilities resulted.
Finally, when hollow micronee:dles were inserted into the skin and left in place, still greater skin permeabilities resulted for those compounds tested. These studies show that microneedles can dramatically increase skin permeability and can thereby increase transport of a number of different compounds across the skin. It also shows that when S solid microneedles are used, a preferred embodiment involves inserting and then removing microneedles, rather than leaving them in place. It also shows that using hollow microneedles are a prefi~rred embodiment over the use of solid microneedles.
In Table 2, the flow rate: of water through hollow silicon microneedles is shown as a function of applied pressure. These data demonstrate that significant flow rates of water 1:0 through microneedles can be achieved at modest pressures.
TABLE 1: Transport of Drugs Through Microneedles Inserted Into Skin Compound No Solid needlesSolid needlesHollow needles inserted inserted needles and removed inserted Calcein * * 4 x 10- I x 10-' 1 x 10-' delive Calcein * * 2 x 10' 1 x 10'' n.a.
removal Insulin ** 1 x 10 I x 10'' n.a.
delive Bovine serum* * 9 x 10 8 x 10~ 9 x 10-' albumin delive Nanoparticle** n.a. 3 x 10-' n.a.
delive ** means that the transport was below the detection limit.
n.a. means that the data are not available.
15 Nanoparticles were made of latex with a diameter of approximately 100 nm.
TABLE 2: Flow Rate of Water Through Hollow Silicon Microneedles as a Function of Applied Pressure Pressure Flow rate ml/min si 1.0 16 1.5 _ 2.0 31 2.5 _ 3.0 45 2.0
According to the present invention, a device for transport of material or energy across biological barriers comprises a plurality of hollow microneedles having a length between 100um and 1mm, and a substrate to which the microneedles are attached or integrally formed, the microneedles extending at an angle from the substrate, wherein the microneedles are made by a microfabrication technique from a material selected from the group consisting of silicon, silicon dioxide, metals, ceramics, and combinations thereof, and wherein each microneedle has a shaft, a portion of which comprises one or more substantially annular bores or channels therethrough and which has a width between about 1um and 100um.
The microneedle devices of embodiments of the invention permit drug delivery or removal of body fluids at clinically relevant rates across skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue. Microneedles can be formed of a variety of materials, including biodegradable or non-biodegradable polymeric materials or metals. In one preferred embodiment, the device includes a means for temporarily securing the microneedle device to the biological barrier to facilitate transport. The device preferably further includes a means for controlling the flow of material through the microneedles. Representative examples of these means include the use of permeable membranes, fracturable impermeable membranes, valves, and pumps, and electrical means.
3a WO 99/645$0 PCT/US99/13226 Methods are provided l:or making solid, porous, or, preferably, hollow microneedles. A preferred method for making a microneedle includes forming a micromold having sidewalls which define the outer surface of the microneedle.
The micromold can be formed, for example, by photolithographically defining one or more holes in a substrate, or by laser based cutting (either serially or by using lithographic projection), or by using a moldl-insert. In a preferred embodiment, the method includes electroplating the sidewalls to form the hollow microneedle, and then removing the micromold from the microneedle.
The microneedle device is useful for delivery of fluid material into or acrass a biological barrier such as skin, wherein the fluid material is delivered from one or more chambers in fluid connection vvith at least one of the microneedles.
Brief Description Of The Drawings Figure 1 is a side eleva~tional view of a preferred embodiment of the microneedle device inserted into human ski .
Figures 2a-a are side cross-sectional views of a method for making microneedles.
Figures 3a-g are side cross-sectional views of a method for making a hollow microneedle.
Figures 4a-d are side cross-sectional views illustrating a preferred method for making hollow microneedles.
:20 Figures Sa-d are side cross-sectional views illustrating a preferred method for making hollow silicon microtubes.
Figures 6a-a are side cross-sectional views illustrating a preferred method for making hollow metal microtub~es.
Figures 7a-d are side cross-sectional views illustrating a preferred method for making tapered metal microneedles.
Figures 8a-d are side cross-sectional views illustrating a method for making tapered microneedies using laser-formed molds.
Figures 9a-f are side cross-sectional views illustrating a second method for making tapered microneedles using laser-formed molds.
Detailed Description Of The Invention 1. Biological Barriers The devices disclosed herein are useful in transport of material into or across biological barriers including the skin (or parts thereof); the blood-brain barrier; mucosal tissue (e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, respiratory); blood vessels; lymphatic vessels; or cell membranes {e.g., for the introduction of material into the interior of a cell or cells). iChe biological barners can be in humans or other types of animals, as well as in plants, insects, or other organisms, including bacteria, yeast, fungi, and embryos.
The microneedle devicE;s can be applied to tissue internally with the aid of a catheter or laparoscope. Far certain applications, such as for drug delivery to an internal LO tissue, the devices can be surgically implanted.
The microneedle device; disclosed herein is typically applied to skin. The stratum corneum is the outer layer, generally between 10 and 50 cells, or between 10 and 20 pm thick. Unlike other tissue in the body, the stratum corneum contains "cells"
(called keratinocytes) filled with bundles of cross-linked keratin and keratohyalin surrounded by an extracellular matrix of lipids. It is this structure that is believed to give skin its barrier properties, which prevents therapeutic transdermal administration of many drugs. Below the stratum corneum is the viable epidermis, which is between 50 and 100 pm thick. The viable epidermis contains no blood vessels, and it exchanges metabolites by diffusion to and from the dermis. Beneath the viable epidermis is the dermis, which is between 1 and ;20 3 mm thick and contains blood vessels, lymphatics, and nerves.
2. The Microneedle Device The microneedle devices disclosed herein include a substrate; one or more microneedles; and, optionally, a reservoir for delivery of drugs or collection of analyte, as well as pump(s), sensor(s), andUor microprocessors) to control the interaction of the foregoing.
a. Substrate The substrate of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites. The substrate includes the base to which the microneedles are attached or integrally formed.
A reservoir may also be attached to the substrate.
b. Microneedle The microneedles of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites.
Preferred materials of construction include pharmaceutical grade stainless steel, gold, titanium, nickel, iron, gold, tin, chromium, copper, alloys of these or other metals, silicon, silicon dioxide, and polymers. lR.epresentative biodegradable polymers include polymers of hydroxy acids such as lactic acid and glycolic acid polylactide, polyglycolide, polylactide-co-glycolide, and copolymers with PEG, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone).
Representative non-biodegradable polymers include polycarbonate, polymethacrylic acid, ethylenevinyl acetate, polytetrafluoroethylene (TEFLONT"'), and polyesters.
Generally, the microneedles should have the mechanical strength to remain intact for delivery of drugs, or serve a;s a conduit for the collection of biological fluid, while being inserted into the skin, while remaining in place for up to a number of days, and while being removed. In embodiments where the microneedles are formed of biodegradable polymers, however, this mechanical requirement is less stringent, since the microneedles or tips thereof can. break off, for example in the skin, and will biodegrade.
Nonetheless, even a biodegradalble microneedle still needs to remain intact at least long enough for the microneedle to serve its intended purpose (e.g., its conduit function).
Therefore, biodegradable microneedles can provide an increased level of safety, as compared to nonbiodegradable .ones. The microneedles should be sterilizable using standard methods.
The microneedles can bc; formed of a porous solid, with or without a sealed coating or exterior portion, or hollow. As used herein, the term "porous"
means having pores or voids throughout at least a portion of the microneedle structure, sufficiently large and sufficiently interconnected to permit passage of fluid and/or solid materials through the microneedle. As used herein, the term "hollow" means having one or more substantially annular bores or channels through the interior of the microneedle structure, having a diameter sufficiently 1<~rge to permit passage of fluid and/or solid materials through the microneedle. The axmular bores may extend throughout all or a portion of the needle in the direction of the tip to the base, extending parallel to the direction of the needle or branching or exiting at a side of the needle, as appropriate. A
solid or porous microneedle can be hollow. One of skill in the art can select the appropriate porosity and/or bore features required for specific applications. For example, one can adjust the pore size or bore diameter to permit passage of the particular material to be transported through the microneedle device.
The microneedles can have straight or tapered shafts. A hollow microneedle that has a substantially uniform diameter, which needle does not taper to a point, is referred to herein as a "microtube." As used herein, the term "microneedle" includes both microtubes and tapered needles unless otherwise indicated. In a preferred embodiment, the diameter of the microneedle; is greatest at the base end of the microneedle and tapers to a point at the end distal the base. The microneedle can also be fabricated to have a shaft that includes both a straight (untapered) portion and a tapered portion.
The microneedles can be formed with shafts that have a circular cross-section in the perpendicular, or the cross-section can be non-circular. For example, the cross-1.5 section of the microneedle can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape. The shaft can have one or more bores. The cross-sectional dimensions typically are between about 10 nm and 1 mm, preferably between 1 micron and microns, and more preferably between 10 and 100 p.m. The outer diameter is typically between about 10 ~m and about 100 pm, and the inner diameter is typically between ~!0 about 3 ~m and about 80 Vim.
The length of the microneedles typically is between about 1 ~m and 1 mm, preferably between 10 microns and 500 microns, and more preferably between 30 and 200 p,m. The length is selected. for the particular application, accounting for both an inserted and uninserted portion. An array of microneedles can include a mixture of 5 microneedles having, for example, various lengths, outer diameters, inner diameters, cross-sectional shapes, and spacings between the microneedles.
The microneedles can be oriented perpendicular or at an angle to the substrate.
Preferably, the microneedles are oriented perpendicular to the substrate so that a larger density of microneedles per unit area of substrate is provided. An array of microneedles 30 can include a mixture of micro:needle orientations, heights, or other parameters.
In a preferred embodiment of the device, the substrate and/or microneedles, as well as other components, are formed from flexible materials to allow the device to fit the contours of the biological barrier, such as the skin, vessel walls, or the eye, to which the device is applied. A flexible device facilitates more consistent penetration during use, since penetration can be limited by deviations in the attachment surface. For example, the surface of human skin is not flat due to dermatoglyphics (i.e. tiny wrinkles) and hair.
c. Reservoir The microneedle device: may include a reservoir in communication with the microneedles. The reservoir can be attached to the substrate by any suitable means. In a l0 preferred embodiment, the reservoir is attached to the back of the substrate {opposite the microneedles) around the periphery, using an adhesive agent (e.g., glue). A
gasket may also be used to facilitate formation of a fluid-tight seal.
In a preferred embodiment, the reservoir contains drug, for delivery through the microneedles. The reservoir may be a hollow vessel, a porous matrix, or a solid form :l5 including drug which is transported therefrom. The reservoir can be formed from a variety of materials that are compatible with the drug or biological fluid contained therein. Preferred materials include natural and synthetic polymers, metals, ceramics, semiconductors, organics, and .composites.
The microneedle device; can include one or a plurality of chambers for storing :ZO materials to be delivered. In th.e embodiment having multiple chambers, each can be in fluid connection with all or a portion of the microneedles of the device array. In one embodiment, at least two chambers are used to separately contain drug (e.g., a lyophilized drug, such as a vaccine) and an administration vehicle (e.g., saline) in order to prevent or minimize degradation during storage. Immediately before use, the contents of the 25 chambers are mixed. Mixing can be triggered by any means, including, for example, mechanical disruption (i.e. puncturing or breaking), changing the porosity, or electrochemical degradation of the walls or membranes separating the chambers.
In another embodiment, a single device is used to deliver different drugs, which are stored separately in different chambers. In this embodiment, the rate of delivery of each drug 30 can be independently controlled.
In a preferred embodiment, the reservoir should be in direct contact with the microneedles and have holes through which drug could exit the reservoir and flow into the interior of hollow or porous microneedles. In another preferred embodiment, the reservoir has holes which permiit the drug to transport out of the reservoir and onto the skin surface. From there, drug :is transported into the skin, either through hollow or porous microneedles, along the sides of solid microneedles, or through pathways created by microneedles in the skin.
d. Transport Control Components The microneedle device also must be capable of transporting material across the barrier at a useful rate. For example, the microneedle device must be capable of delivering drug across the skin ;~t a rate sufficient to be therapeutically useful. The device may include a housing with microelectronics and other micromachined structures to control the rate of delivery either according to a preprogrammed schedule or through active interface with the patient., a healthcare professional, or a biosensor.
The rate can be controlled by manipulating a variety of factors, including the characteristics of the drug formulation to be delivered (e.g., its viscosity, electric charge, and chemical composition); the dimensions o:f each microneedle (e.g., its outer diameter and the area of porous or hollow openings); the number of microneedles in the device; the application of a driving force (e.g., a concentration gradient, a voltage gradient, a pressure gradient); and the use of a valve.
The rate also can be controlled by interposing between the drug in the reservoir and the openings) at the base end of the microneedle polymeric or other materials selected for their diffusion char<~cteristics. For example, the material composition and layer thickness can be manipulated using methods known in the art to vary the rate of diffusion of the drug of interest through the material, thereby controlling the rate at which the drug flows from the reservoir through the microneedle and into the tissue.
Transportation of molecules through the microneedles can be controlled or monitored using, for example, various combinations of valves, pumps, sensors, actuators, and microprocessors. These components can be produced using standard manufacturing or microfabrication techniques. Actuators that may be useful with the microneedle devices disclosed herein include; micropumps, microvalves, and positioners. In a preferred embodiment, a microprocessor is programmed to control a pump or valve, thereby controlling the rate of delivery.
Flow of molecules through the microneedles can occur based on diffusion, capillary action, or can be induced using conventional mechanical pumps or nonmechanical driving forces, such as electroosmosis or electrophoresis, or convection.
For example, in electroosmosis, electrodes are positioned on the biological barrier surface, one or more microneedles, and/or the substrate adjacent the needles, to create a convective flow which carries appositely charged ionic species and/or neutral molecules toward or into the biological barrier. In a preferred embodiment, the microneedle device J! 0 is used in combination with another mechanism that enhances the permeability of the biological barrier, for example by increasing cell uptake or membrane disruption, using electric fields, ultrasound, chemical enhancers, vacuum viruses, pH, heat and/or light.
Passage of the micronec;dles, or drug to be transported via the microneedles, can be manipulated by shaping the microneedle surface, or by selection of the material 1.5 forming the microneedle surface (which could be a coating rather than the microneedle per se). For example, one or more grooves on the outside surface of the microneedles can be used to direct the passage of drug, particularly in a liquid state.
Alternatively, the physical surface properties of the microneedle can be manipulated to either promote or inhibit transport of material along the microneedle surface, such as by controlling ~!0 hydrophilicity or hydrophobicit:y.
The flow of molecules c;an be regulated using a wide range of valves or gates.
These valves can be the type that are selectively and repeatedly opened and closed, or they can be single-use types. For example, in a disposable, single-use drug delivery device, a fracturable barrier or one-way gate may be installed in the device between the ~!5 reservoir and the opening of thc; microneedles. When ready to use, the barrier can be broken or gate opened to permit flow through the microneedles. Other valves or gates used in the microneedle devices can be activated thermally, electrochemically, mechanically, or magnetically 1:a selectively initiate, modulate, or stop the flow of molecules through the needles. In a prefen:ed embodiment, flow is controlled by using a ;40 rate-limiting membrane as a "valve."
The microneedle devices can further include a flowmeter or other means to monitor flow through the micra~needles and to coordinate use of the pumps and valves.
e. Sensors Useful sensors may include sensors of pressure, temperature, chemicals, and/or electro-magnetic fields. Biosensors can be located on the microneedle surface, inside a hollow or porous microneedle, ~or inside a device in communication with the body tissue via the microneedle (solid, hollow, or porous). These microneedle biosensors can include four classes of principal transducers: potentiometric, amperometric, optical, and physiochemical. An amperome:tric sensor monitors currents generated when electrons are exchanged between a biological system and an electrode. Blood glucose sensors frequently are of this type.
The microneedle may function as a conduit for fluids, solutes, electric charge, light, or other materials. In one embodiment, hollow microneedles can be filled with a substance, such as a gel, that has a sensing functionality associated with it.
In an application for sensing based on binding to a substrate or reaction mediated by an enzyme, the substrate or enzyme can be immobilized in the needle interior, which would be especially useful in a porous needle to create an integral needle/sensor.
Wave guides can be incorporated into the microneedle device to direct light to a specific location, or for detection, for example, using means such as a pH dye for color evaluation. Similarly, heat, ele<;tricity, light or other energy forms may be precisely transmitted to directly stimulate, damage, or heal a specific tissue or intermediary {e.g., tattoo remove for dark skinned lpersons), or diagnostic purposes, such as measurement of blood glucose based on IR spectra or by chromatographic means, measuring a color change in the presence of immobilized glucose oxidase in combination with an appropriate substrate.
f. Attachment Features A collar or flange also can be provided with the device, for example, around the periphery of the substrate or the base. It preferably is attached to the device, but alternatively can be formed as an integral part of the substrate, for example by forming microneedles only near the center of an "oversized" substrate. The collar can also emanate from other parts of the device. The collar can provide an interface to attach the microneedle array to the rest ojP the device, and can facilitate handling of the smaller devices.
In a preferred embodiment, the microneedle device includes an adhesive to temporarily secure the device to the surface of the biological barrier. The adhesive can be essentially anywhere on the device to facilitate contact with the biological barrier. For example, the adhesive can be on the surface of the collar (same side as microneedles), on the surface of the substrate between the microneedles (near the base of the microneedles), or a combination thereof.
g. Transdermal Micron.eedle Device :l0 Figure I is a side elevational view of a schematic of a preferred embodiment of the microneedle device inserted into skin. The device 10 includes an upper portion or substrate 11 from which a plurality of microneedles 12 protrude. The height of the upper portion 11 is between about 1 l,~m and 1 cm, and the width of the upper portion is between about 1 mm and 10 em. The upper portion 11 of the device can be solid or hollow, and '.l5 may include multiple compartments. In a preferred embodiment for drug delivery, the upper portion 11 contains one or more drugs to be delivered. It is also preferred that the upper portion include one or more sensors and/or an apparatus (e.g., pump or electrode) to drive (provide/direct the force) transport of the drug or other molecules.
The height (or length) of the microneedles 12 generally is between about 1 ~m 20 and I mm. The diameter and length both affect pain as well as functional properties of the needles. In transdermal apI>lications, the "insertion depth" of the microneedles 12 is preferably less than about 100 lam, more preferably about 30 ~,m, so that insertion of the microneedles 12 into the skin through the stratum corneum 14 does not penetrate past the epidermis 16 into the dermis lg (as described below), thereby avoiding contacting nerves :!5 and reducing the potential for causing pain. In such applications, the actual length of the microneedles may be longer, since the portion of the microneedles distal the tip may not be inserted into the skin; the uninserted length depends on the particular device design and configuration. The actual (overall) height or length of microneedles 12 should be equal to the insertion depth plus the uninserted length.
:10 The diameter of each microneedle 12 generally is between about 10 nm and 1 mm, and preferably leaves a residual hole (following microneedle insertion and withdrawal) of less than about 1 pm, to avoid making a hole which would allow bacteria to enter the penetration wound. The actual microneedle diameter should be larger than 1 p,m, since the hole likely will contract following withdrawal of the microneedle. The diameter of microneedle 12 more preferably is between about 1 ~m and 100 p.m.
Larger diameter and longer microneedles are acceptable, so long as the microneedle can penetrate the biological barrier to the desired depth and the hole remaining in the skin or other tissue following withdrawal of the microneedle is sufficiently small, preferably small enough to exclude bacteriial entry. The microneedles 12 can be solid or porous, and can include one or more bores connected to upper portion 11.
l.0 3. Methods of Making Micro~needle Devices The microneedle devices are made by microfabrication processes, by creating small mechanical structures in :>ilicon, metal, polymer, and other materials.
These microfabrication processes are based on well-established methods used to make integrated circuits, electronic packages and other microelectronic devices, augmented by additional methods used in the field of micromachining. The microneedle devices can have dimensions as small as a few nanometers and can be mass-produced at low per-unit costs.
a. Microfabrication Processes Microfabrication processes that may be used in making the microneedles f,0 disclosed herein include lithography; etching techniques, such as wet chemical, dry, and photoresist removal; thermal oxidation of silicon; electroplating and electroless plating;
diffusion processes, such as boron, phosphorus, arsenic, and antimony diffusion; ion implantation; film deposition, such as evaporation (filament, electron beam, flash, and shadowing and step coverage), sputtering, chemical vapor deposition (CVD), epitaxy 2.5 (vapor phase, liquid phase, and molecular beam), electroplating, screen printing, lamination, stereolithography, laser machining, and laser ablation (including projection ablation). See generally Jaeger, Introduction to Microelectronic Fabrication (Addison-Wesley Publishing Co., Reading MA 1988); Runyan, et al., Semiconductor Integrated Circuit Processing Technology (Addison-Wesley Publishing Co., Reading MA
1990);
3~0 Proceedings of the IEEE Micro Electro Mechanical Systems Conference 1987-1998; Rai-Choudhury, ed., Handbook of Iviicrolithographv. Micromachining &
Microfabrication (SPIE Optical Engineering Press, Bellingham, WA 1997).
The following methods are preferred for making microneedles.
i. electrochemical etching of silicon In this method, electrochemical etching of solid silicon to porous silicon is used to create extremely fine (on the order of 0.01 ~,m) silicon networks which can be used as piercing structures. This method uses electrolytic anodization of silicon in aqueous hydrofluoric acid, potentially in combination with light, to etch channels into the silicon.
By varying the doping concentavation of the silicon wafer to be etched, the electrolytic ).0 potential during etching, the iinc;ident light intensity, and the electrolyte concentration, control over the ultimate pore structure can be achieved. The material not etched (i.e. the silicon remaining) forms the miicroneedles. This method has been used to produce irregular needle-type structures measuring tens of nanometers in width.
ii. plasma etching 1.5 This process uses deep plasma etching of silicon to create microneedles with diameters on the order of 0.1 p.m or larger. Needles are patterned directly using photolithography, rather than indirectly by controlling the voltage (as in electrochemical etching), thus providing greater control over the final microneedle geometry.
In this process, an appropriate masking material (e.g., metal) is deposited onto a silicon wafer substrate and patterned into dots having the diameter of the desired microneedles. The wafer is then subjected to a carefully controlled plasma based on fluorine/oxygen chemistries to etch very deep, high aspect ratio trenches into the silicon.
See, e.g., Jansen, et al., "The Black Silicon Method IV: The Fabrication of Three-Dimensional Structures in Silicon with High Aspect Ratios for Scanning Probe 5 Microscopy and Other Applications," IEEE Proceedings of Micro Electro Mechanical Systems Conference, pp. 88-93 (1995). Those regions protected by the metal mask remain and form the needles. 'This method is further described in Example 1 below.
iii. electroplating In this process, a metal payer is first evaporated onto a planar substrate. A
layer of ~~0 photoresist is then deposited onto the metal to form a patterned mold which leaves an exposed-metal region in the shape of needles. By electroplating onto the exposed regions of the metal seed layer, the mold bounded by photoresist can be filled with electroplated material. Finally, the substrate and photoresist mold are removed, leaving the finilshed microneedle array. The microneedles produced by this process generally have diameters on the order of 1 pm or larger. See, e.g., Frazier, et al., "Two dimensional metallic microelectrode arrays for extracellular stimulation and recording of neurons", IEEE
Proceedings of the Micro Elec~'ro Mechanical Systems Conference, pp. I 95-200 ( 1993).
iv. other processes Another method for forming microneedles made of silicon or other materials is to use microfabrication techniques such as photolithography, plasma etching, or laser :10 ablation to make a mold form (A), transfernng that mold form to other materials using standard mold transfer techniques, such as embossing or injection molding (B), and reproducing the shape of the oziginal mold form (A) using the newly-created mold (B) to yield the final microneedles (C). Alternatively, the creation of the mold form (A) could be skipped and the mold (B) could be microfabricated directly, which could then be used TS to create the final microneedles~ (C).
Another method of fornaing solid silicon microneedles is by using epitaxial growth on silicon substrates, as is utilized by Containerless Research, Inc.
(Evanston, Illinois, USA) for its products.
b. Hollow or Porous Microneedles ~!0 In a preferred embodiment, microneedles are made with pores or other pathways through which material may be transported. The following descriptions outline representative methods for fabricating either porous or hollow microneedles.
i. porous microneedles Rather than having a single, well-defined hole down the length of the needle, ~;5 porous needles are filled with a network of channels or pores which allow conduction of fluid or energy through the needle shaft. It has been shown that by appropriate electrochemical oxidation of silicon, pore arrays with high aspect ratios and a range of different pore size regimes can be formed; these pore regimes are defined as ( I ) microporous regime with average pore dimensions less than 2 nm, (2) mesoporous regime a0 with average pore sizes of betvs~een 2 nm and 50 zun, and (3) macroporous regime with pores greater than SO nm. The mesoporous and macroporous regimes are expected to be most useful for drug delivery. 'Two approaches to porous needles are generally available, either (a) the silicon wafer is first made porous and then etched as described above to form needles or (b) solid microneedles are etched and then rendered porous, for example, by means of electrochemical oxidation, such as by anodization of a silicon substrate in a hydrofluoric acid electrolyte. 7.'he size distribution of the etched porous structure is highly dependent on several variables, including doping kind and illumination conditions, as detailed in Lehmann, "Porou.s Silicon--A New Material for MEMS", IEEE
Proceedings of the Micro Electro Mechanical Systems Conference, pp. 1-6 (1996).
Porous polymer or metallic microneedles can be formed, for example, by micromolding a 1.0 polymer containing a volatilizalble or teachable material, such as a volatile salt, dispersed in the polymer or metal, and thf,n volatilizing or leaching the dispersed material, leaving a porous polymer matrix in the shape of the microneedle.
ii. hollow needles Three-dimensional arrays of hollow rnicroneedles can be fabricated, for example, l 5 using combinations of dry etching processes (Laermer, et al., "Bosch Deep Silicon Etching: Improving Uniformity and Etch Rate for Advanced MEMS Applications,"
Micro Electro Mechanical Systems, Orlando, Fl, USA, (Jan. 17-21, 1999);
Despont et aL, "High-Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photoresist for MEMS", Proc.
of IEEE 10'h Annual InternatiorTal Workshop on MEMS, Nagoya, Japan, pp. S 18-522 (Jan.
2;0 26-30, 1997)); micromold creation in lithographically-defined and/or laser ablated polymers and selective sidewall. electroplating; or direct micromolding techniques using epoxy mold transfers.
One or more distinct and continuous pathways are created through the interior of microneedles. In a preferred embodiment, the microneedle has a single annular pathway 2.5 along the center axis of the microneedle. This pathway can be achieved by initially chemically or physically etching the holes in the material and then etching away microneedles around the hole. .Alternatively, the microneedles and their holes can be made simultaneously or holes can be etched into existing microneedles. As another option, a microneedle form or mold can be made, then coated, and then etched away, ?~0 leaving only the outer coating to form a hollow microneedle. Coatings can be formed either by deposition of a film on by oxidation of the silicon microneedles to a specific thickness, followed by removal of the interior silicon. Also, holes from the backside of the wafer to the underside of the hollow needles can be created using a front-to-backside infrared alignment followed by etching from the backside of the wafer.
a. silicon microneedles S One method for hollow needle fabrication is to replace the solid mask used in the formation of solid needles by a mask that includes a solid shape with one or more interior regions of the solid shape removed. One example is a "donut-shaped" mask.
Using this type of mask, interior regions of the needle are etched simultaneously with their side walls. Due to lateral etching of the inner side walls of the needle, this may not produce sufficiently sharp walls. In that case, two plasma etches may be used, one to form the outer walls of the microneedle (i.e., the 'standard' etch), and one to form the inner hollow core (which is an extremely anisotropic etch, such as in inductively-coupled-plasma "ICP" etch). For example, the I:C;P etch can be used to form the interior region of the needle followed by a second photolithography step and a standard etch to form the outer walls of the microneedle. Figure 2a represents a silicon wafer 82 with a patterned photoresist layer 84 on top of the wafer 82. The wafer 82 is anisotropically etched (Figure 2b) to form a cavity 86 through its entire thickness (Figure 2c). The wafer 82 is then coated with a chromium layer 88 followed by a second photoresist layer 90 patterned so as to cover the cavity 86 and form a circular mask for subsequent etching (Figure 2d).
The wafer 82 is then etched by ;a standard etch to form the outer tapered walls 92 of the microneedle (Figure 2e).
Alternatively, this structure can be achieved by substituting the chromium mask used for the solid microneedles described in Example 1 by a silicon nitride layer 94 on the silicon substrate 95 covered with chromium 96, deposited as shown in Figure 3a and patterned as shown in Figure 3b~. Solid microneedles are then etched as described in Example 1 as shown Figure 3c, the chromium 96 is stripped (Figure 3d), and the silicon 95 is oxidized to form a thin layer of silicon dioxide 97 on all exposed silicon surfaces (Figure 3e). The silicon nitride layer 94 prevents oxidation at the needle tip. The silicon nitride 94 is then stripped (Figure 3f), leaving exposed silicon at the tip of the needle and oxide-covered silicon 97 everywhere else. The needle is then exposed to an ICP
plasma which selectively etches the inr.~er sidewalls of the silicon 95 in a highly anisotropic manner to form the interior hole of the needle (Figure 3g).
Another method uses the solid silicon needles described previously as 'forts' around which the actual needle structures are deposited. After deposition, the forms are etched away, yielding the hollow structures. Silica needles or metal needles can be formed using different methods. Silica needles can be formed by creating needle structures similar to the ICP neE:dles described above prior to the oxidation described above. The wafers are then oxidized to a controlled thickness, forming a layer on the shaft of the needle form which will eventually become the hollow microneedle.
The silicon nitride is then stripped and the silicon core selectively etched away (e.g., in a wet alkaline solution) to form a hollow silica microneedle.
In a preferred embodimc;nt, an array of hollow silicon microtubes is made using deep reactive ion etching combined with a modified black silicon process in a conventional reactive ion etches, as described in Example 3 below. First, arrays of circular holes are patterned through photoresist into Si02 , such as on a silicon wafer.
Then the silicon can be etched using deep reactive ion etching (DRIE) in an inductively coupled plasma (ICP) reactor to etch deep vertical holes. The photoresist was then removed. Next, a second photolithography step patterns the remaining Si02 layer into circles concentric to the holes, leaving ring shaped oxide masks surrounding the holes.
The photoresist is then removedl and the silicon wafer again deep silicon etched, such that the holes are etched completely through the wafer (inside the Si02 ring) and simultaneously the silicon is etched around the Si02 ring leaving a cylinder.
This latter process can be varied to produce hollow, tapered microneedles.
After an array of holes is fabricated as described above, the photoresist and Si02 layers are replaced with conformal DC sputtered chromium rings. The second ICP etch is replaced with a SF6/02 plasma etch in a reactive ion etches (RIE), which results in positively sloping outer sidewalls. Henry, et al., "Micromachined Needles for the Transdermal Delivery of Drugs," Micro Electro Mechanical Systems, Heidelberg, Germany, pp.
498 (Jan. 26-29, 1998).
b. metal ,mieroneedles Metal needles can be foamed by physical vapor deposition of appropriate metal layers on solid needle forms, which can be made of silicon using the techniques described above, or which can be formed using other standard mold techniques such as embossing or injection molding. The metals are selectively removed from the tips of the needles using electropolishing techniques, in which an applied anodic potential in an electrolytic solution will cause dissolution of metals more rapidly at sharp points, due to concentration of electric field lines at the sharp points. Once the underlying silicon needle forms have been exposed at the tips, the silicon is selectively etched away to form hollow metallic needle structurca. This process could also be used to make hollow needles made from other materials by depositing a material other than metal on the needle forms and following the procedure described above.
A preferred method of fabricating hollow metal microneedles utilizes micromold plating techniques, which are dfacribed as follows and in Examples 4 and S. In a method for making metal microtubes, which does not require dry silicon etching, a photo-defined mold first is first produced, for .example, by spin casting a thick layer, typically 1 SO lun, of an epoxy (e.g., SU-8) onto a substrate that has been coated with a thin sacrificial layer, typically about 10 to 50 nm. .A~xays of cylindrical holes are then photolithographieally defined through the epoxy layer, which typically is about 150 p,m thick.
(Despont, et al., "High-Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photoresist fox MEMS,''' Proc.
of IEEE 10'h Annual International Workshop on MEMS, Nagoya, Japan, pp. 518-522 (Jan.
26-30, 1997)). The diameter of these cylindrical holes defines the outer diameter of the tubes. The upper surface of the substrate, the sacrificial layer, is then partially removed at the bottom of the cylindrical holes in the photoresist. The exact method chosen depends on the choice of substrate. For example, the process has been successfully performed on silicon and glass substrates (in which the upper surface is etched using isotropic wet or dry etching techniques) and copper-clad printed wiring board substrates. In the latter case, the copper laminate is selectively removed using wet etching. Then a seed layer, such as Ti/Cu/Ti (e.g., 30 nm/21)0 nm/30 nm), is conformally DC sputter-deposited onto the upper surface of the epoxy mold and onto the sidewalls of the cylindrical holes. The seed layer should be electrically isolated from the substrate. Subsequently, one or more electroplatable metals or alloys, such as Ni, NiFe, Au, Cu, or Ti, are electroplated onto the seed layer. The surrounding epoxy is then removed, leaving microtubes which each have an interior annular hole that extends through the base metal supporting the tubes.
The rate and duration of electra~plating is controlled in order to define the wall thickness and inner diameter of the micro~tubes. In one embodiment, this method was used to produce microtubes having a hc;ight of between about 150 and 250 pm, an outer diameter of between about 40 and 120 ~Cm, and an inner diameter of between about 30 and 110 ~m (i.e., having a wall thickness of 10 p,m). In a typical array, the microtubes have a tube center-to-center spacing of about 150 p,m, but can vary depending on the desired needle l.0 density.
A variation of this method is preferred for forming tapered microneedles. .As described above, photolithography yields holes in the epoxy which have vertical sidewalls, such that the resulting shafts of the microneedles are straight, not tapered. This vertical sidewall limitation can be overcome by molding a preexisting 3D
structure, i.e., a mold-insert. The subsequent removal of the mold-insert leaves a mold which can be surface plated similarly to the holes produced by photolithography described above.
Alternatively, non-vertical sidewalk can be produced directly in the polymeric mold into which electroplating will take place. For example, conventional photoresists known in the art can be exposed and developed in such as way as to have the surface 2;0 immediately adjacent to the mask be wider than the other surface.
Specialized greyscale photoresists in combination with greyscale masks can accomplish the same effect. Laser-ablated molds can also be made: with tapered sidewalk, e.g., by optical adjustment of the beam (in the case of serial hole fabrication) or of the reticle or mold during ablation (in the case of projection ablation).
Z;5 To form hollow tapered microneedles, the mold-insert is an array of solid silicon microneedles, formed as described in Henry, et al., "Micromachined Needles for the Transdermal Delivery of Drugs;'" Micro Electro Mechanical Systems, Heidelberg, Germany, Jan. 26-29, pp. 494-498 (1998). First, a layer of a material, such as an epoxy (e.g., SU-8 or a polydimethylsil.oxane ("PDMS")), is spin cast onto the array of silicon ?~0 microneedles to completely blanket the entire array. 'the epoxy settles during pre-bake to create a planar surface above the silicon needle tips; the material is then fully pre-baked, photolithographically cross-linls;ed, and post-baked.
The upper surface of the: epoxy is then etched away, for example with an plasma, until the needle tips are exposed, preferably leaving between about 1 and S p,m of tip protruding from the epoxy. 'The silicon is then selectively removed, for example by using a SF6 plasma or a HN03/13F solution. The remaining epoxy micromold is the negative of the microneedles and has a small diameter hole where the tip of the microneedle formerly protruded.
After the removal of the silicon, a seed layer, such as Ti-Cu-Ti, is conformally sputter-deposited onto the epoxy micromold. Following the same process sequence described for hollow metal microtubes, one or more electroplatable metals or alloys, such as Ni, NiFe, Au, or Cu, are electroplated onto the seed layer. Finally, the epoxy is removed, for example by using .an 02/CHF3 plasma, leaving an array of hollow metal microneedles. An advantage of using PDMS in this application is that the micromold can be physically removed from the silicon mold insert by mechanical means, such as peeling, without damaging the silicon mold insert, thus allowing the silicon mold insert to be reused. Furthermore, the electroplated microneedles can be removed from the PDMS
mold by mechanical means, for example by peeling, thereby allowing the PDMS to also be reused. In a preferred embodliment, this method is used to produce microneedles 2'0 having a height of between about 150 and 250 p,m, an outer diameter of between about 40 and 120 ~tm, and an inner diameter of between about 50 and 100 p,m. In a typical array, the microtubes have a tube centc,r-to-center spacing of about 150 Vim, but can vary depending on the desired needle density. The microneedles are 150 ~m in height with a base diameter of $0 p,m, a tip di,~neter of 10 p,m, and a needle-to-needle spacing of 1 SO
2.5 pm.
c. silicon dioxide microneedles Hollow microneedles formed of silicon dioxide can be made by oxidizing the surface of the silicon microneedle forms (as described above), rather than depositing a metal and then etching away the solid needle forms to leave the hollow silicon dioxide 30 structures. This method is illustrated in Figures 4a-4d. Figure 4a shows an array 24 of needle forms 26 with masks 28 on their tips. In Figure 4b, the needle forms 26 have been coated with a layer 30 of metal, silicon dioxide or other material. Figure 4c shows the coated needle forms 26 with the: masks 28 removed. Finally, in Figure 4d, the needle forms 26 have been etched away, leaving hollow needles 30 made of metal, silicor<
dioxide, or other materials.
In one embodiment, hollow, porous, or solid microneedles are provided with longitudinal grooves or other modifications to the exterior surface of the microneedles.
Grooves, for example, should be useful in directing the flow of molecules along the outside of microneedles.
d. op Iyme~r microneedles In a preferred method, polymeric microneedles are made using microfabricated molds. For example, the epoxy molds can be made as described above and injection molding techniques can be appliied to form the microneedles in the molds (Weber, et al., "Micromolding - a powerful tool for the large scale production of precise microstructures", Proc. SPIE - International Soc. Optical Engineer. 2879, 156-167 (1996);
Schift, et al., "Fabrication of replicated high precision insert elements for micro-optical bench arrangements" Proc. SPIN - International Soc. Optical Engineer. 3513, (1998). These micromolding techniques are preferred over other techniques described herein, since they can provide relatively less expensive replication, i.e.
lower cost of mass production. In a preferred embodiment, the polymer is biodegradable.
2~D 4. Microneedle Device Applications The device may be used for single or multiple uses for rapid transport across a biological barrier or may be left in place for longer times (e.g., hours or days) for long-term transport of molecules. Depending on the dimensions of the device, the application site, and the route in which the device is introduced into (or onto) the biological barrier, 2.5 the device may be used to introdluce or remove molecules at specific locations.
As discussed above, Figure 1 shows a side elevational view of a schematic of a preferred embodiment of the mi~,roneedle device 10 in a transdermal application. The device 10 is applied to the skin such that the microneedles 12 penetrate through the stratum corneum and enter the viable epidermis so that the tip of the microneedle at least 3~D penetrates into the viable epidermis. In a preferred embodiment, drug molecules in a reservoir within the upper portion 11 flow through or around the microneedles and into the viable epidermis, where the drug molecules then diffuse into the dermis for local treatment or for transport through the body.
To control the transport of material out of or into the device through the microneedles, a variety of forcea or mechanisms can be employed. These include S pressure gradients, concentration gradients, electricity, ultrasound, receptor binding, heat, chemicals, and chemical reactions. Mechanical or other gates in conjunction with the forces and mechanisms describE:d above can be used to selectively control transport of the material.
In particular embodiments, the device should be "user-friendly." For example, in some transdermal applications, affixing the device to the skin should be relatively simple, and not require special skills. This embodiment of a microneedle may include an array of microneedles attached to a housing containing drug in an internal reservoir, wherein the housing has a bioadhesive coating around the microneedles. The patient can remove a peel-away backing to expose an adhesive coating, and then press the device onto a clean IS part of the skin, leaving it to administer drug over the course of, for example, several days.
a. Drug Delivery Essentially any drug or other bioactive agents can be delivered using these devices. Drugs can be proteins, enzymes, polysaccharides, polynucleotide molecules, and synthetic organic and inorganic compounds. Representative agents include anti-infectives, hormones, such as insulin, growth regulators, drugs regulating cardiac action or blood flow, and drugs for pain control. The drug can be for local treatment or for regional or systemic therapy. The following are representative examples, and disorders they are used to treat:
Calcitonin, osteoporosis; Enoxaprin, anticoagulant; Etanercept, rheumatoid arthritis; Erythropoietin, anemia; Fentanyl, postoperative and chronic pain;
Filgrastin, low white blood cells from chemotherapy; Heparin, anticoagulant; Insulin, human, diabetes;
Interferon Beta 1 a, multiple sclerosis; Lidocaine, local anesthesia;
Somatropin, growth hormone; and Sumatriptan, migraine headaches.
In this way, many drugs can be delivered at a variety of therapeutic rates.
The rate can be controlled by varying a number of design factors, including the outer diameter of the microneedle, the number and size of pores or channels in each microneedle, the number of microneedles in an array, the magnitude and frequency of application of the force driving the drug through the microneedle and/or the holes created by the microneedles. For example, devices designed to deliver drug at different rates might have more microneedles for more rapid delivery and fewer microneedles for less rapid delivery. As another example, a device designed to deliver drug at a variable rate could vary the driving force (e.g., preasure gradient controlled by a pump) for transport according to a schedule which 'was pre-programmed or controlled by, for example, the user or his doctor. The devices can be affixed to the skin or other tissue to deliver drugs :LO continuously or intermittently, for durations ranging from a few seconds to several hours or days.
One of skill in the art can measure the rate of drug delivery for particular microneedle devices using in mstro and in vivo methods known in the art. For example, to measure the rate of transdermal drug delivery, human cadaver skin mounted on standard :l5 diffusion chambers can be usedl to predict actual rates. See Hadgraft &
Guy, eds., Transdermal Drug Delivery: Developmental Issues and Research Initiatives (Marcel Dekker, New York 1989); Bronaugh & Maibach, Percutaneous Absorption, Mechanisms--Methodol~;,v--Drug Delivery (Marcel Dekker, New York 1989). After filling the compartment on the dermis side of the diffusion chamber with saline, a microneedle array :!0 is inserted into the stratum corneum; a drug solution is placed in the reservoir of the microneedle device; and samples of the saline solution are taken over time and assayed to determine the rates of drug transport.
In an alternate embodiment, biodegradable or non-biodegradable microneedles can be used as the entire drug delivery device, where biodegradable microneedles are a :!5 preferred embodiment. For ex~unple, the microneedles may be formed of a biodegradable polymer containing a dispersion of an active agent for local or systemic delivery. The agent could be released over tune, according to a profile determined by the composition and geometry of the microneedles, the concentration of the drug and other factors. In this way, the drug reservoir is within the matrix of one or more of the microneedles.
;10 In another alternate embodiment, these microneedles may be purposefully sheared off from the substrate after penetrating the biological barrier. In this way, a portion of the microneedles would remain within or on the other side of the biological barrier and a portion of the microneedles and their substrate would be removed from the biological barner. In the case of skin, this could involve inserting an array into the skin, manually or otherwise breaking off the microneedles tips and then remove the base of the microneedles. The portion of the microneedles which remains in the skin or in or across another biological barrier could then release drug over time according to a profile determined by the composition and geometry of the microneedles, the concentration of the drug and other factors. In a~ preferred embodiment, the microneedles are made of a biodegradable polymer. The release of drug from the biodegradable microneedle tips can :l0 be controlled by the rate of polymer degradation. Microneedle tips can release drugs for local or systemic effect, or othc;r agents, such as perfume, insect repellent and sun block.
Microneedle shape and content can be designed to control the breakage of microneedles. For example, a notch can be introduced into microneedles either at the time of fabrication or as a subsequent step. In this way, microneedles would :l5 preferentially break at the site of the notch. Moreover, the size and shape of the portion of microneedles which break off c;an be controlled not only for specific drug release patterns, but also for specific interactions with cells in the body. For example, objects of a few microns in size are known to be taken up by macrophages. The portions of microneedles that break off carp be controlled to be bigger or smaller than that to prevent :'0 uptake by macrophages or can be that size to promote uptake by macrophages, which can be desirable for delivery of vaccines.
b. Dia nostic Sensing of Body Fluids (Biosensors~
One embodiment of the devices described herein may be used to remove material from the body across a biological barrier, i.e. for minimally invasive diagnostic sensing.
5 For example, fluids can be transported from interstitial fluid in a tissue into a reservoir in the upper portion of the device.. The fluid can then be assayed while in the reservoir or the fluid can be removed from the reservoir to be assayed, for diagnostic or other purposes. For example, interstitial fluids can be removed from the epidermis across the stratum corneum to assay for glucose concentration, which should be useful in aiding :30 diabetics in determining their required insulin dose. Other substances or properties that would be desirable to detect ine:lude lactate (important for athletes), oxygen, pH, alcohol, tobacco metabolites, and illegal drugs (important for both medical diagnosis and law enforcement).
The sensing device can be in or attached to one or more microneedles, or in a housing adapted to the substrate. Sensing information or signals can be transferred optically (e.g., refractive index) or electrically (e.g., measuring changes in electrical impedance, resistance, current, voltage, or combination thereof). For example, it may be useful to measure a change as a function of change in resistance of tissue to an electrical current or voltage, or a change in response to channel binding or other criteria (such as an optical change) wherein different resistances are calibrated to signal that more or less :l0 flow of drug is needed, or that delivery has been completed.
In one embodiment, onE: or more microneedle devices can be used for (1) withdrawal of interstitial fluid, (2) assay of the fluid, and/or (3) delivery of the appropriate amount of a therapeutic agent based on the results of the assay, either automatically or with human intervention. For example, a sensor delivery system may be :l5 combined to form, for example, a system which withdraws bodily fluid, measures its glucose content, and delivers a~i appropriate amount of insulin. The sensing or delivery step also can be performed using conventional techniques, which would be integrated into use of the microneedle device. For example, the microneedle device could be used to withdraw and assay glucose, arid a conventional syringe and needle used to administer the :?0 insulin, or vice versa.
In an alternate embodiment, microneedles may be purposefully sheared off from the substrate after penetrating tike biological barrier, as described above.
The portion of the microneedles which remain within or on the other side of the biological barrier could contain one or more biosensors. For example, the sensor could change color as its output.
5 For microneedles sheared off in the skin, this color change could be observed through the skin by visual inspection or with the aid of an optical apparatus.
Other than transport of drugs and biological molecules, the microneedles rnay be used to transmit or transfer other materials and energy forms, such as light, electricity, heat, or pressure. The microneedles, for example, could be used to direct light to specific ;30 locations within the body, in order that the light can directly act on a tissue or on an intermediary, such as light-sen:>itive molecules in photodynamic therapy. The microneedles can also be used for aerosolization or delivery for example directly to a mucosal surface in the nasal or buccal regions or to the pulmonary system.
The microneedle devices disclosed herein also should be useful for controlling transport across tissues other than skin. For example, microneedles can be inserted into the eye across, for example, conjunctiva, sclera, and/or cornea, to facilitate delivery of drugs into the eye. Similarly, microneedles inserted into the eye can facilitate transport of fluid out of the eye, which may be of benefit for treatment of glaucoma.
Microneedles may also be inserted into the bu~ccal (oral), nasal, vaginal, or other accessible mucosa to facilitate transport into, out of, or across those tissues. For example, a drug may be l.0 delivered across the buccal muc;osa for local treatment in the mouth or for systemic uptake and delivery. As another example, microneedle devices may be used internally within the body on, for example, the lining of the gastrointestinal tract to facilitate uptake of orally-ingested drugs or the lining of blood vessels to facilitate penetration of drugs into the vessel wall. For examfde, cardiovascular applications include using microneedle l.5 devices to facilitate vessel distension or immobilization, similarly to a stmt, wherein the microneedles/substrate can function as a "staple-like" device to penetrate into different tissue segments and hold their relative positions for a period of time to permit tissue regeneration. This application could be particularly useful with biodegradable devices.
These uses may involve invasive procedures to introduce the microneedle devices into the ~:0 body or could involve swallowing, inhaling, injecting or otherwise introducing the devices in a non-invasive or minimally-invasive manner.
The present invention will be further understood with reference to the following non-limiting examples.
Example 1: Fabrication of Sa~lid Silicon Microneedles 2:5 A chromium masking miaterial was deposited onto silicon wafers and patterned into dots having a diameter approximately equal to the base of the desired microneedles.
The wafers were then loaded into a reactive ion etcher and subjected to a carefully controlled plasma based on fluorine/oxygen chemistries to etch very deep, high aspect ratio valleys into the silicon. Tlhose regions protected by the metal mask remain and form ?~0 the microneedles.
<100>-oriented, prime grade, 450-550 ~m thick, 10-15 S2-cm silicon wafers (Nova Electronic Materials Tnc;., Richardson, TX) were used as the starting material. The wafers were cleaned in a solutiion of 5 parts by volume deionized water, 1 part 30%
hydrogen peroxide, and 1 part 30% ammonium hydroxide (J.T. Baker, Phillipsburg, NJ) at approximately 80°C for 15 minutes, and then dried in an oven (Blue M
Electric, Watertown, WI) at 150°C for 10 minutes. Approximately 1000 A of chromium (Mat-Vac Technology, Flagler Beach, FL) was deposited onto the wafers using a DC-sputterer (601 Sputtering System, CVC Products, Rochester, NY). The chromium layer was patterned into 20 by 20 arrays of 80 pm .diameter dots with 150 p,m center-to-center spacing using the lithographic process described below.
A layer of photosensitive material (1827 photoresist, Shipley, Marlborough, MA) was deposited onto the chromium layer covering the silicon wafers. A standard lithographic mask (Telic, Santa Monica, CA) bearing the appropriate dot array pattern was positioned on top of the photoresist layer. The wafer and photoresist were then exposed to ultraviolet (UV) light through the mask by means of an optical mask aligner (Hybralign Series 500, Optical Associates, Inc., Milpitas, CA). The exposed photoresist was removed by soaking the wafers in a liquid developer (354 developer, Shipley, Marlborough, MA) leaving the: desired dot array of photoresist on the chromium layer.
Subsequently, the wafers were dipped into a chromium etchant (CR-75; Cyanteck:
Fremont, CA), which etched the chromium that had been exposed during the photolithography step, leaving dot arrays of chromium (covered with photoresist) on the surface of the silicon wafer. The photoresist still present on the chromium dots formed the masks needed for fabrication of the microneedles, described below.
The microneedles were fabricated using a reactive ion etching techniques based .25 on the Black Silicon Method developed at the University of Twente. The patterned wafers were etched in a reactive ion etcher (700 series wafer/batch Plasma Processing System, Plasma Therm, St. Petersburg, FL) with means for ensuring good thermal contact between the wafers and the underlying platen (Apiezon N, K.J. Lesker, Clairton, PA).
The wafers were etched using the following gases and conditions: SF6 (20 standard cubic centimeters per minute) and O > ( 15 standard cubic centimeters per minute) at a pressure of 150 mTorr and a power of 150 W for a run time of approximately 250 minutes.
These conditions caused both deep vertical etching and slight lateral underetching.
By controlling the ratio of flow rates of the SF6 and 02 gases used to form the plasma, the aspect ratio of the microneedles could be adjusted. The regions protected by the chromium masks remained and formed the microneedles. Etching was allowed to proceed until the masks fell off' due to underetching, resulting in an array of sharp silicon spikes.
Example 2: Transdermal Transport Using Solid Microneedles To determine if microfa.bricated microneedles could be used to enhance transdermal drug delivery, axra;ys of microneedles were made using a deep plasma etching J.0 technique. Their ability to penc;trate human skin without breaking was tested and the resulting changes in transderma~l transport were measured.
Arrays of microneedles were fabricated having extremely sharp tips (radius of curvature less than 1 pm), and are approximately 150 pm long. Because the skin surface is not flat due to dermatoglyphics and hair, the full length of these microneedles will not l.5 penetrate the skin. All experiments were performed at room temperature (232°C).
The ability of the microneedles to pierce skin without breaking was then tested.
Insertion of the arrays into skin required only gentle pushing. Inspection by light and electron microscopy showed that more than 95% of microneedles within an array pierced across the stratum corneum of the epidermis samples. Moreover, essentially all of the ~;0 microneedles that penetrated the epidermis remained intact. On those very few which broke, only the top 5-10 p,m wa.s damaged. Microneedle arrays could also be removed without difficulty or additional damage, as well as re-inserted into skin multiple times.
To quantitatively assess the ability of microneedles to increase transdermal transport, calcein permeability of human epidermis with and without inserted microneedle 2;5 arrays was measured. Calcein crosses skin very poorly under normal circumstances and therefore represents an especially difficult compound to deliver. As expected, passive permeability of calcein across unaltered skin was very low, indicating that the epidermis samples were intact.
Insertion of microneedlc;s into skin was capable of dramatically increasing ?~0 permeability to calcein. When microneedles were inserted and left embedded in the skin, calcein permeability was increased by more than 1000-fold. Insertion of microneedles for s, followed by their removal, yielded an almost 10,000-fold increase. Finally, insertion of a microneedle array for 1 h, followed by its removal, increased skin permeability by about 25,000-i:old. Permeabilities for skin with microneedles inserted and then removed are higher tr~an for skin with microneedles remaining embedded 5 probably because the micronee;dles themselves or the silicon plate supporting the array may block access to the micro:ecopic holes created in the skin. Light microscopy showed that the holes which remained :in the skin after microneedles were removed were approximately 1 ~m in size.
To confirm in vitro experiments which showed that skin permeability can be 10 significantly increased by microneedles, studies were conducted with human volunteers.
They indicated that microneedl',es could be easily inserted into the skin of the forearm or hand. Moreover, insertion of nnicroneedle arrays was never reported to be painful, but sometimes elicited a mild "we~~ring" sensation described as a weak pressure or the feeling of a piece of tape affixed to the: skin. Although transport experiments were not performed in vivo, skin electrical resistance was measured before and after microneedle insertion.
Microneedles caused a 50-fold drop in skin resistance, a drop similar to that caused by the insertion of a 30-gauge "macroneedle." Inspection of the site immediately after microneedle insertion showed no holes visible by light microscopy. No erythema, edema, or other reaction to microneedles was observed over the hours and days which followed.
:20 This indicates that microneedle; arrays can permeabilize skin in human subjects in a non-painful and safe manner.
Example 3: Fabrication of Silicon Microtubes Three-dimensional arrays of rnicrotubes were fabricated from silicon, using deep reactive ion etching combined with a modified black silicon process in a conventional :25 reactive ion etcher. The fabrication process is illustrated in Figures Sa-d. First, arrays of 40 pm diameter circular holes 32 were patterned through photoresist 34 into a 1 pm thick Si02 layer 36 an a two inch siliicon wafer 38 (Figure Sa). The wafer 38 was then etched using deep reactive ion etching; (DRIE) (Laermer, et al., "Bosch Deep Silicon Etching:
Improving Uniformity and Etclh Rate for Advanced MEMS Applications," Micro Electro 30 Mechanical Systems, Orlando, Florida, USA (Jan. 17-21, 1999)). in an inductively coupled plasma (ICP) reactor to etch deep vertical holes 40. The deep silicon etch was stopped after.the holes 40 are approximately 200 ~m deep into the silicon substrate 38 (Figure Sb) and the photoresist 34 was removed. A second photolithography step patterned the remaining Si02 layer 36 into circles concentric to the holes, thus leaving ring shaped oxide masks 34 swTOUnding the holes (Figure Sc). The photoresist 34 was then removed and the wafer 38 was again deep silicon etched, while simultaneously the holes 40 were etched completely through the wafer 38 (inside the SiOZ ring) and the silicon was etched around the Si02 ring 38 leaving a cylinder 42 (Figure Sd).
The resulting tubes were 150 pm in height, with an outer diameter of 80 Vim, an inner diameter of 40 pm, and a tube center-to-center spacing of 300 N.m.
l.0 Example 4: Micromold Fabrication of Metal Microtubes Hollow metal microtubes were prepared without dry silicon etching, using a thick, photo-defined mold of epoxy. 'The sequences are illustrated in Figures 6a-e.
First, a thick layer of SU-8 epoxy 44 was spin cast onto a silicon or glass substrate 46 that had been coated with 30 nm of titanium 48, the sacrificial layer. Arrays of cylindrical holes 49 l.5 were then photolithographically defined through an epoxy layer 44, typically 150 ~m thick (Figure 6a). The sacrificial layer then was partially removed using a wet etching solution containing hydrofluoric acid and water at the bottom of the cylindrical holes in the SU-8 photoresist 46 (Figure: 6b). A seed layer of Ti/Cu/Ti (30 nm/200 nm/30 nm) 39 was then conformally DC sputter-deposited onto the upper surface of the epoxy mold and 20 onto the sidewalls of the cylindrical holes 49 (Figure 6c). As shown in Figure 6c, the seed layer 39 was electrically isolated from the substrate. Subsequently, NiFe was electroplated onto the seed layer 39 (Figure 6d), the epoxy 44 was removed from the substrate, and the surrounding epoxy 44 was removed (Figure 6e). The resulting microtubes are 200 pm in height with an outer diameter of 80 Vim, an inner diameter of 60 2.5 pm, and a tube center-to-center spacing of 150 p,m. T'he holes in the interior of the microtubes protrude through the base metal supporting the tubes.
Example 5: Micromold Fabrication of Tapered Microneedles A micromold having tapered walls was fabricated by molding a preexisting 3-D
array of microneedles, i.e. the mold-insert, and subsequently removing the mold insert.
?'~0 The micromold was then surface plated in a manner similar to that for the microtubes described in Example 4. The fabrication sequence is illustrated in Figures 7a-7d.
First, an array of solid silicon microneedles 50 were prepared as described in Henry, et al., "Micromachined Needles for the Transdermal Delivery of Drugs,"
Micro Electro Mechanical Systems, Hfeidelberg, Germany, Jan. 26-29, pp. 494-498 (1998).
Then, a layer of epoxy 52 (SU-8) was spin cast onto the microneedle array to completely blanket the array (Figure 7a). 'Che epoxy 52 settled during pre-bake to create a planar surface above the tips of the miicroneedles 50. The epoxy 52 was then fully pre-baked, photolithographically cross-linlked, and post-baked.
Then, the upper surface of the epoxy 52 was etched away using an O2/CHF3 plasma until approximately 1 to 2 p,m of the needle tips 54 were exposed, protruding from a0 the epoxy 52 (Figure 7b). The silicon was then selectively removed by using a SF6 plasma (Figure 7c). The remaining epoxy mold 52 provided a negative of the microneedles with a small diameter hole where the tip of the silicon needle protruded.
After the removal of the silicon, a seed layer of Ti-Cu-Ti 54 was conformally sputter-deposited onto the top and sidewalk of the epoxy micromold 52. Following the same :l5 process sequence as described iin Example 4, NiFe was then electroplated onto the seed layer 54 (Figure 7c). Finally, tlhe epoxy was removed using an Oz/CHF3 plasma, leaving a 20 x 20 array of NiFe hollow metal microneedles 54 (Figure 7d). The microneedles 54 were 1 SO p.m in height with a base diameter of 80 p,m, a tip diameter of 10 Vim, and a needle-to-needle spacing of 151) pm.
20 Micromold-based microneedles also have been successfully manufactured using a process in which the epoxy mold material was replaced with PDMS. In this case, it was possible to remove the mold from the mold insert, as well as the microneedles from the mold, using only physical techniques such as peeling. This approach advantageously requires no dry etching and allows one to reuse both the mold and the mold insert.
25 Example 6: Micromold Fabrication of Tapered Microneedles Using Laser-Formed Molds A micromold having tapered walls was fabricated by use of laser ablation techniques, as shown in Figurea 8a-d. A laser-ablatable polymer sheet 60 such as KAPTONTM polyimide approximately 150 microns in thickness was optionally laminated ;30 to a thin (10-30 micron) metal sheet 62 such as titanium (Figure 8a). A
tapered hole 64 was formed in the metal/polymer laminate 60/62 using a laser technique such as excimer WO 99/64580 PC'T/US99/13226 laser ablation,(Figure 8b). The entry hole of the laser spot was on the metal side 62, and a through hole was made through. both the metal sheet and the polymer film. The through hole 64 was tapered in combination with either defocusing or appropriate substrate motion to create a taper such that the wide end of the hole 64 (typically 40-50 microns) was on the metal side 62 and the narrow end of the hole 64 (typically 10-20 microns) was on the polymer 60 side. A thin layer of metal 66, e.g. titanium, of thickness 0.1 micron was then deposited, e.g., using a sputter-deposition technique, in such a way that the metal 66 deposited on the metal. film side and coated the polymer sidewalls, but did not coat the polymer 60 side of the laminate (Figure 8c). Electrodeposition of metal 68, e.g., gold, to a thickness of 1 to 5 microns was then performed on the titanium-coated metal surface 66, and polymer sidewalls curved section of 60 next to 64. Finally, the polymer 60 was removed, using e.g. an oxygen plasma, to form the completed microneedles (Figure 8d).
Alternate polymer removal methods, such as thermal, solvent, aqueous, or photo-degradation followed by solvent or aqueous removal, are also possible if the polymer material is chosen appropriately (e.g., a photoresist resin).
Example 7: Formation of Mi~.roneedles by Embossing Formation of a micronee;dle by embossing is shown in Figures 9a-9f. A
polymeric layer 70 (Figure 9a) is embossed by a solid microneedle or microneedle array 72 (F figure 9b). The array 72 is removed (Figure 9c), and the layer 70 is etched from the non-embossed side 74 until the embossed cavity 76 is exposed (Figure 9d). A
metallic layer 78 is then deposited on the embossed side and the sidewalls, but not on the non-embossed side 74 (Figure 9e). This layer '78 is optionally thickened by electrodeposition of an additional metal layer 80 on top of it (Figure 9e). The polymer layer 70 is then removed to form the microneedles 78/80 (Figure 9f).
Example 8: Transdermal Application of Hollow Microneedles The bore of hollow microneedles must provide fluid flow with minimal clogging in order to be suitable to transport material, such as in transdermal drug delivery.
Therefore, microneedles and microtubes were evaluated to determine their suitability for these functions.
Hollow metal and silicon microneedles, produced as described in Examples 3-5, were inserted through human skin epidermis with no apparent clogging of the needle bores. Scanning electron microscopy of a hollow metal (NiFe) microneedle penetrating up through the underside of hurnan epidermis showed the microneedle remains intact, with the tip free of debris. Simiilarly, silicon microneedles, metal microneedles, and metal microtubes were successfully ir.~serted through human skin. Also, the hollow microneedles were shown to permit the flow of water through their bores.
Example 9: Drug Transporit Through Microneedles Inserted Into Skin Studies were performed with solid and hollow microneedles to demonstrate transport of molecules and fluidls. As shown in Table 1, transport of a number of different compounds across skin is possible using microneedles. These studies were performed using either solid silicon microneedles or using hollow silicon microneedles made by methods described in this patent. Transport was measured across human cadaver epidermis in vitro using Franz dliffusion chambers at 37 °C using methods described in S.
Henry, D. McAllister, M.G. Allen, and M.R. Prausnitz, "Microfabricated microneedles:
A novel method to increase transdermal drug delivery" J. Pharm. Sci. 87: 922-25 (1998).
The transdermal delivery of calcein, insulin, bovine serum albumin and nanoparticles was measured. Delivery refers to the ability to transport these compounds from the stratum corneum side of the epidermis to the viable epidermis side.
This is the direction of transport associated. with delivering drugs into the body.
Removal of calcein was also measured. Removal refers to the ability to transport calcein from the viable epidermis side of the epidermis to the stratum corneum side. This is the direction of transport associated with removing from the body compounds found in the body, such as glucose.
In all cases shown in Talble 1, transport of these compounds across skin occurred at levels below our detection Iinait when no needles were inserted into the skin. Intact skin provides an excellent barrier to transport of these compounds. In all cases examined, when solid microneedles were inserted into the skin and left in place, large skin permeabilities were measured, indicating that the microneedles had created pathways for transport across the skin. Furthermore, in all cases, when solid microneedles were inserted into the skin and then removed, even greater skin permeabilities resulted.
Finally, when hollow micronee:dles were inserted into the skin and left in place, still greater skin permeabilities resulted for those compounds tested. These studies show that microneedles can dramatically increase skin permeability and can thereby increase transport of a number of different compounds across the skin. It also shows that when S solid microneedles are used, a preferred embodiment involves inserting and then removing microneedles, rather than leaving them in place. It also shows that using hollow microneedles are a prefi~rred embodiment over the use of solid microneedles.
In Table 2, the flow rate: of water through hollow silicon microneedles is shown as a function of applied pressure. These data demonstrate that significant flow rates of water 1:0 through microneedles can be achieved at modest pressures.
TABLE 1: Transport of Drugs Through Microneedles Inserted Into Skin Compound No Solid needlesSolid needlesHollow needles inserted inserted needles and removed inserted Calcein * * 4 x 10- I x 10-' 1 x 10-' delive Calcein * * 2 x 10' 1 x 10'' n.a.
removal Insulin ** 1 x 10 I x 10'' n.a.
delive Bovine serum* * 9 x 10 8 x 10~ 9 x 10-' albumin delive Nanoparticle** n.a. 3 x 10-' n.a.
delive ** means that the transport was below the detection limit.
n.a. means that the data are not available.
15 Nanoparticles were made of latex with a diameter of approximately 100 nm.
TABLE 2: Flow Rate of Water Through Hollow Silicon Microneedles as a Function of Applied Pressure Pressure Flow rate ml/min si 1.0 16 1.5 _ 2.0 31 2.5 _ 3.0 45 2.0
Claims (12)
1. A device for transport of material or energy across biological barriers comprising:
a plurality of hollow microneedles having a length between 100µ and lmm, and a substrate to which the microneedles are attached or integrally formed, the microneedles extending at an angle from the substrate, wherein the microneedles are made by a microfabrication technique from a material selected from the group consisting of silicon, silicon dioxide, metals, ceramics, and combinations thereof, and wherein each microneedle has a shaft, a portion of which comprises one or more substantially annular bores or channels therethrough and which has a width between about lµ and 100µ
.
a plurality of hollow microneedles having a length between 100µ and lmm, and a substrate to which the microneedles are attached or integrally formed, the microneedles extending at an angle from the substrate, wherein the microneedles are made by a microfabrication technique from a material selected from the group consisting of silicon, silicon dioxide, metals, ceramics, and combinations thereof, and wherein each microneedle has a shaft, a portion of which comprises one or more substantially annular bores or channels therethrough and which has a width between about lµ and 100µ
.
2. The device of claim 1, wherein the microfabrication technique is a micromachining technique selected from the group consisting of lithography, plasma etching, wet chemical etching, dry etching, thermal oxidation of silicon, electroplating, electroless plating, boron diffusion, phosphorus diffusion, arsenic diffusion, antimony diffusion, ion implantation, film deposition, sputtering, chemical vapor deposition, epitaxy, chemical anodization, electrochemical anodization, and combinations thereof.
3. The device of claim 1, wherein the material comprises a metal.
4. The device of claim 3, wherein the material consists essentially of metal.
5. The device of any one of claims 1 to 4, wherein the width of the entire shaft of the microneedles is between about 1µ and 100µ
.
.
6. The device of any one of claims 1 to 5, wherein the length of the microneedles is between about 100µ and 500µ.
7. The device of any one of claims 1 to 6, wherein the microneedles are in communication with a reservoir.
8. The device of claim 7, wherein the reservoir contains a drug.
9. The device of claim 8, wherein the drug comprises insulin.
10. The device of any one of claims 1 to 9, wherein one or more of the microneedles each comprise a base end which tapers to a sharp tip end, wherein the width of the base end is between about 10µ and 100µ.
11. The device of any one of claims 1 to 10, wherein the angle is about 90°.
12. The device of any one of claims 1 to 11, wherein the substrate comprises a metal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002510389A CA2510389A1 (en) | 1998-06-10 | 1999-06-10 | Microneedle devices and methods of manufacture and use thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/095,221 US6503231B1 (en) | 1998-06-10 | 1998-06-10 | Microneedle device for transport of molecules across tissue |
US09/095,221 | 1998-06-10 | ||
US09/316,229 US6334856B1 (en) | 1998-06-10 | 1999-05-21 | Microneedle devices and methods of manufacture and use thereof |
US09/316,229 | 1999-05-21 | ||
PCT/US1999/013226 WO1999064580A1 (en) | 1998-06-10 | 1999-06-10 | Microneedle devices and methods of manufacture and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002510389A Division CA2510389A1 (en) | 1998-06-10 | 1999-06-10 | Microneedle devices and methods of manufacture and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2330207A1 CA2330207A1 (en) | 1999-12-16 |
CA2330207C true CA2330207C (en) | 2005-08-30 |
Family
ID=26789971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002330207A Expired - Fee Related CA2330207C (en) | 1998-06-10 | 1999-06-10 | Microneedle devices and methods of manufacture and use thereof |
Country Status (6)
Country | Link |
---|---|
US (1) | US20020138049A1 (en) |
EP (1) | EP1086214B1 (en) |
JP (1) | JP2002517300A (en) |
AU (1) | AU767122B2 (en) |
CA (1) | CA2330207C (en) |
WO (1) | WO1999064580A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11931040B2 (en) | 2016-03-01 | 2024-03-19 | Kitotech Medical, Inc. | Microstructure-based systems, apparatus, and methods for wound closure |
US11957346B2 (en) | 2022-02-18 | 2024-04-16 | Kitotech Medical, Inc. | Force modulating deep skin staples and instruments |
US11986613B2 (en) | 2020-02-19 | 2024-05-21 | Kitotech Medical, Inc. | Microstructure systems and methods for pain treatment |
Families Citing this family (344)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6922576B2 (en) | 1998-06-19 | 2005-07-26 | Becton, Dickinson And Company | Micro optical sensor device |
GB9815820D0 (en) * | 1998-07-22 | 1998-09-16 | Secr Defence | Improvements relating to micro-machining |
US6535753B1 (en) | 1998-08-20 | 2003-03-18 | Microsense International, Llc | Micro-invasive method for painless detection of analytes in extra-cellular space |
EP1187653B1 (en) | 1999-06-04 | 2010-03-31 | Georgia Tech Research Corporation | Devices for enhanced microneedle penetration of biological barriers |
US6256533B1 (en) * | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6312612B1 (en) * | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
US6379324B1 (en) | 1999-06-09 | 2002-04-30 | The Procter & Gamble Company | Intracutaneous microneedle array apparatus |
US6802811B1 (en) | 1999-09-17 | 2004-10-12 | Endoluminal Therapeutics, Inc. | Sensing, interrogating, storing, telemetering and responding medical implants |
US6331266B1 (en) * | 1999-09-29 | 2001-12-18 | Becton Dickinson And Company | Process of making a molded device |
US6919009B2 (en) | 1999-10-01 | 2005-07-19 | Nanoplex Technologies, Inc. | Method of manufacture of colloidal rod particles as nanobarcodes |
US7045049B1 (en) * | 1999-10-01 | 2006-05-16 | Nanoplex Technologies, Inc. | Method of manufacture of colloidal rod particles as nanobar codes |
US8465468B1 (en) * | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
US6511463B1 (en) * | 1999-11-18 | 2003-01-28 | Jds Uniphase Corporation | Methods of fabricating microneedle arrays using sacrificial molds |
US6982058B2 (en) | 1999-12-08 | 2006-01-03 | Baxter International, Inc. | Method for fabricating three dimensional structures |
ES2282153T3 (en) | 1999-12-08 | 2007-10-16 | Baxter International Inc. (A Delaware Corporation) | PROCEDURE FOR THE MANUFACTURE OF A MICROPOROUS FILTER MEMBRANE. |
US20010053891A1 (en) * | 1999-12-30 | 2001-12-20 | Ackley Donald E. | Stacked microneedle systems |
US6406638B1 (en) * | 2000-01-06 | 2002-06-18 | The Regents Of The University Of California | Method of forming vertical, hollow needles within a semiconductor substrate, and needles formed thereby |
US6558361B1 (en) | 2000-03-09 | 2003-05-06 | Nanopass Ltd. | Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems |
US6659982B2 (en) * | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6565532B1 (en) | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
US6537242B1 (en) * | 2000-06-06 | 2003-03-25 | Becton, Dickinson And Company | Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance |
US6607513B1 (en) * | 2000-06-08 | 2003-08-19 | Becton, Dickinson And Company | Device for withdrawing or administering a substance and method of manufacturing a device |
US9717451B2 (en) | 2000-06-08 | 2017-08-01 | Becton, Dickinson And Company | Device for withdrawing or administering a substance and method of manufacturing a device |
US6603987B2 (en) * | 2000-07-11 | 2003-08-05 | Bayer Corporation | Hollow microneedle patch |
GB0017999D0 (en) * | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
US6533949B1 (en) | 2000-08-28 | 2003-03-18 | Nanopass Ltd. | Microneedle structure and production method therefor |
AU8877401A (en) | 2000-09-08 | 2002-03-22 | Alza Corp | Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
JP2002079499A (en) * | 2000-09-08 | 2002-03-19 | Terumo Corp | Method of manufacturing needle-like article, and manufactured needle |
EP1337694A4 (en) * | 2000-10-02 | 2004-09-15 | Surromed Inc | Method of manufacture of colloidal rod particles as nanobarcodes |
GB0025147D0 (en) | 2000-10-13 | 2000-11-29 | Torsana Diabetes Diagnostics A | Optical sensor for in situ measurement of analytes |
IL155375A0 (en) | 2000-10-13 | 2003-11-23 | Alza Corp | Microblade array impact applicator |
HUP0303576A2 (en) | 2000-10-13 | 2004-01-28 | Alza Corp | Microprotrusion member retainer for impact applicator |
US7419481B2 (en) | 2000-10-13 | 2008-09-02 | Alza Corporation | Apparatus and method for piercing skin with microprotrusions |
AU9682801A (en) | 2000-10-13 | 2002-04-22 | Alza Corp | Apparatus and method for piercing skin with microprotrusions |
US6821281B2 (en) | 2000-10-16 | 2004-11-23 | The Procter & Gamble Company | Microstructures for treating and conditioning skin |
US7828827B2 (en) | 2002-05-24 | 2010-11-09 | Corium International, Inc. | Method of exfoliation of skin using closely-packed microstructures |
HUP0302924A2 (en) | 2000-10-26 | 2003-12-29 | Alza Corp | Transdermal drug delivery devices having coated microprotrusions |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US6638246B1 (en) | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
NL1016779C2 (en) | 2000-12-02 | 2002-06-04 | Cornelis Johannes Maria V Rijn | Mold, method for manufacturing precision products with the aid of a mold, as well as precision products, in particular microsieves and membrane filters, manufactured with such a mold. |
EP1345646A2 (en) * | 2000-12-14 | 2003-09-24 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
DE10063634B4 (en) * | 2000-12-20 | 2006-01-12 | Liebl, Horst, Zelsheim | Device and method for introducing an active substance into the skin |
AU2002231207A1 (en) | 2000-12-21 | 2002-07-01 | Biovalve Technologies, Inc. | Microneedle array systems |
US6697668B2 (en) * | 2001-01-25 | 2004-02-24 | Iomed, Inc. | Ocular iontophoretic device and method for using the same |
AU2002250011A1 (en) * | 2001-02-05 | 2002-08-19 | Becton, Dickinson And Company | Microprotrusion array and methods of making a microprotrusion |
US6663820B2 (en) | 2001-03-14 | 2003-12-16 | The Procter & Gamble Company | Method of manufacturing microneedle structures using soft lithography and photolithography |
US6855372B2 (en) | 2001-03-16 | 2005-02-15 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
CN100349632C (en) | 2001-04-20 | 2007-11-21 | 阿尔扎公司 | Microprojection array having beneficial agent contg coating |
EP3251722B1 (en) | 2001-04-20 | 2020-06-17 | ALZA Corporation | Microprojection array having a beneficial agent containing coating and method of forming the coating thereon |
US6591124B2 (en) * | 2001-05-11 | 2003-07-08 | The Procter & Gamble Company | Portable interstitial fluid monitoring system |
US6721586B2 (en) | 2001-06-12 | 2004-04-13 | Lifescan, Inc. | Percutaneous biological fluid sampling and analyte measurement devices and methods |
US6793632B2 (en) | 2001-06-12 | 2004-09-21 | Lifescan, Inc. | Percutaneous biological fluid constituent sampling and measurement devices and methods |
US6875613B2 (en) | 2001-06-12 | 2005-04-05 | Lifescan, Inc. | Biological fluid constituent sampling and measurement devices and methods |
US6501976B1 (en) | 2001-06-12 | 2002-12-31 | Lifescan, Inc. | Percutaneous biological fluid sampling and analyte measurement devices and methods |
US6837988B2 (en) | 2001-06-12 | 2005-01-04 | Lifescan, Inc. | Biological fluid sampling and analyte measurement devices and methods |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US6767341B2 (en) | 2001-06-13 | 2004-07-27 | Abbott Laboratories | Microneedles for minimally invasive drug delivery |
US6844213B2 (en) * | 2001-06-14 | 2005-01-18 | Integrated Sensing Systems | Process of forming a microneedle and microneedle formed thereby |
US20030073609A1 (en) * | 2001-06-29 | 2003-04-17 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
US6881203B2 (en) | 2001-09-05 | 2005-04-19 | 3M Innovative Properties Company | Microneedle arrays and methods of manufacturing the same |
US20040087992A1 (en) * | 2002-08-09 | 2004-05-06 | Vladimir Gartstein | Microstructures for delivering a composition cutaneously to skin using rotatable structures |
AU2002327675A1 (en) * | 2001-09-19 | 2003-04-01 | Biovalve Technologies, Inc. | Microneedles, microneedle arrays, and systems and methods relating to same |
CA2500452A1 (en) | 2001-09-28 | 2003-04-03 | Biovalve Technologies, Inc. | Switchable microneedle arrays and systems and methods relating to same |
AU2002337788A1 (en) | 2001-09-28 | 2003-04-07 | Biovalve Technologies, Inc. | Microneedle with membrane |
US6893431B2 (en) | 2001-10-15 | 2005-05-17 | Scimed Life Systems, Inc. | Medical device for delivering patches |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
US7004928B2 (en) * | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
AU2003209645A1 (en) | 2002-03-04 | 2003-09-16 | Nano Pass Technologies Ltd. | Devices and methods for transporting fluid across a biological barrier |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
CN1655834A (en) | 2002-05-06 | 2005-08-17 | 贝克顿·迪金森公司 | Method and device for controlling drug pharmacokinetics |
US7303726B2 (en) | 2002-05-09 | 2007-12-04 | Lifescan, Inc. | Minimal procedure analyte test system |
US7060192B2 (en) | 2002-05-09 | 2006-06-13 | Lifescan, Inc. | Methods of fabricating physiological sample collection devices |
CA2490137C (en) * | 2002-06-25 | 2012-01-03 | Sung-Yun Kwon | Rapidly dissolving micro-perforator for drug delivery and other applications |
CN102872526A (en) | 2002-07-19 | 2013-01-16 | 3M创新有限公司 | Microneedle devices and microneedle delivery apparatus |
EP1539282A2 (en) * | 2002-08-06 | 2005-06-15 | GenVec, Inc. | Improved injection system |
US7001669B2 (en) | 2002-12-23 | 2006-02-21 | The Administration Of The Tulane Educational Fund | Process for the preparation of metal-containing nanostructured films |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
KR100563330B1 (en) * | 2003-01-16 | 2006-03-22 | 포스트마이크로 주식회사 | Method for manufacturing of polymer micro needle array with liga process |
DE10307487A1 (en) * | 2003-02-21 | 2004-09-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Methods and devices for the injury-free movement of a probe through biological cell material |
JP4565193B2 (en) | 2003-04-23 | 2010-10-20 | バレリタス, インコーポレイテッド | Hydraulically operated pump for long duration pharmaceutical administration |
US7572405B2 (en) * | 2003-06-02 | 2009-08-11 | Corium International Inc. | Method for manufacturing microstructures having hollow microelements using fluidic jets during a molding operation |
JP2005021677A (en) * | 2003-06-10 | 2005-01-27 | Medorekkusu:Kk | Pad base for percutaneous administration and injection needle |
JP2005021678A (en) * | 2003-06-10 | 2005-01-27 | Medorekkusu:Kk | Pad base for percutaneous admistration and its manufacturing method |
IL156374A0 (en) | 2003-06-10 | 2004-01-04 | Danenberg Holdings 2000 Ltd N | Method for removing a pigmented section of skin |
CA2528512A1 (en) | 2003-06-10 | 2004-12-16 | Medrx Co., Ltd. | Process for producing pad base for transdermal drug administration, pad base for transdermal drug administration and needle |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US6921670B2 (en) * | 2003-06-24 | 2005-07-26 | Hewlett-Packard Development Company, Lp. | Nanostructure fabrication using microbial mandrel |
AU2004255228A1 (en) * | 2003-06-30 | 2005-01-20 | Alza Corporation | Method for coating skin piercing microprojections |
EP1638523B8 (en) | 2003-06-30 | 2013-12-25 | ALZA Corporation | Formulations for coated microprojections containing non-volatile counterions |
JP2007503268A (en) | 2003-08-25 | 2007-02-22 | スリーエム イノベイティブ プロパティズ カンパニー | Delivery of immune response modifying compounds |
CN1842355A (en) * | 2003-08-26 | 2006-10-04 | 阿尔扎公司 | Device and method for intradermal cell implantation |
IL157696A0 (en) | 2003-09-01 | 2004-03-28 | Hawk Medical Technologies Ltd | Apparatus and method for removing a pigmented section of skin |
JP2007503958A (en) * | 2003-09-03 | 2007-03-01 | ライフパッチ インターナショナル,インコーポレイテッド | Personal diagnostic equipment and related methods |
US7488343B2 (en) | 2003-09-16 | 2009-02-10 | Boston Scientific Scimed, Inc. | Medical devices |
US8353861B2 (en) | 2003-09-18 | 2013-01-15 | Texmac, Inc. | Applicator for applying functional substances into human skin |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
BRPI0415466A (en) | 2003-10-24 | 2006-12-19 | Alza Corp | pretreatment method and system for enhancing transdermal drug delivery |
US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
CN1897882A (en) | 2003-10-28 | 2007-01-17 | 阿尔扎公司 | Method and apparatus for reducing the incidence of tobacco use |
JP4682144B2 (en) | 2003-10-31 | 2011-05-11 | アルザ・コーポレーシヨン | Self-actuating applicator for microprojection arrays |
DE10353629A1 (en) * | 2003-11-17 | 2005-06-16 | Lts Lohmann Therapie-Systeme Ag | Device for the transdermal administration of active substances |
KR20070011252A (en) * | 2003-11-21 | 2007-01-24 | 알자 코포레이션 | Ultrasound assisted transdermal vaccine delivery method and system |
WO2005065765A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Medical devices and kits including same |
EP1706026B1 (en) | 2003-12-31 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Method and apparatus for improving fluidic flow and sample capture |
GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
US8551391B2 (en) | 2004-02-17 | 2013-10-08 | Avery Dennison Corporation | Method of making microneedles |
JP2007523771A (en) * | 2004-02-23 | 2007-08-23 | スリーエム イノベイティブ プロパティズ カンパニー | Microneedle array molding method |
US8137397B2 (en) | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
US8915957B2 (en) | 2004-03-11 | 2014-12-23 | Alcatel Lucent | Drug delivery stent |
CN100540086C (en) * | 2004-03-12 | 2009-09-16 | 新加坡科技研究局 | Be used for making the method and the mould of side-ported microneedles |
AU2005228145B2 (en) | 2004-03-24 | 2011-03-03 | Corium Pharma Solutions, Inc. | Transdermal delivery device |
CA2579145C (en) * | 2004-04-01 | 2023-06-27 | The General Hospital Corporation | Method and apparatus for dermatological treatment and tissue reshaping |
AU2005235990A1 (en) * | 2004-04-13 | 2005-11-03 | Alza Corporation | Apparatus and method for transdermal delivery of multiple vaccines |
US7591806B2 (en) * | 2004-05-18 | 2009-09-22 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
EP1751546A2 (en) | 2004-05-20 | 2007-02-14 | Albatros Technologies GmbH & Co. KG | Printable hydrogel for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
US7150904B2 (en) * | 2004-07-27 | 2006-12-19 | Ut-Battelle, Llc | Composite, ordered material having sharp surface features |
WO2006018642A1 (en) | 2004-08-16 | 2006-02-23 | Functional Microstructures Limited | Method of producing a microneedle or microimplant |
SE0402100D0 (en) * | 2004-08-30 | 2004-08-30 | Bonsens Ab | Molded micro-needles |
US7132054B1 (en) * | 2004-09-08 | 2006-11-07 | Sandia Corporation | Method to fabricate hollow microneedle arrays |
US20060062836A1 (en) * | 2004-09-21 | 2006-03-23 | Carter Stephen G | Methods of device-assisted drug delivery |
EP1819379B1 (en) | 2004-11-18 | 2016-08-31 | Nanopass Technologies Ltd. | System for delivering fluid into flexible biological barrier |
WO2006055844A2 (en) | 2004-11-18 | 2006-05-26 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
CN101060883B (en) | 2004-11-18 | 2010-06-23 | 3M创新有限公司 | Low-profile microneedle array applicator |
US8057842B2 (en) | 2004-11-18 | 2011-11-15 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
AU2005306426B2 (en) * | 2004-11-18 | 2011-04-28 | 3M Innovative Properties Company | Masking method for coating a microneedle array |
AU2005306429B2 (en) | 2004-11-18 | 2011-04-14 | 3M Innovative Properties Company | Microneedle array applicator and retainer |
US20080009801A1 (en) * | 2004-12-02 | 2008-01-10 | Nickel Janice H | Method for dispensing material into a drug delivery device |
CA2589733C (en) | 2004-12-07 | 2014-02-11 | 3M Innovative Properties Company | Method of molding a microneedle |
JP5882556B2 (en) * | 2004-12-28 | 2016-03-09 | ナブテスコ株式会社 | Skin needle, skin needle manufacturing apparatus, and skin needle manufacturing method |
JPWO2006075689A1 (en) * | 2005-01-14 | 2008-06-12 | 久光製薬株式会社 | Medicinal product carrying device and method for producing the same |
JP5053645B2 (en) * | 2005-01-14 | 2012-10-17 | 久光製薬株式会社 | Medicinal product carrying device and method for producing the same |
WO2006080508A1 (en) * | 2005-01-31 | 2006-08-03 | Bioserentach Co., Ltd. | Transdermal absorption preparation, sheet holding transdermal absorption preparation and transdermal absorption preparation holder |
GB0505244D0 (en) * | 2005-03-15 | 2005-04-20 | Ivmd Uk Ltd | Diagnostic apparatus |
AU2006230308A1 (en) * | 2005-03-28 | 2006-10-05 | Alza Corporation | Microprojections with capillary control features and method |
EP1869414A4 (en) | 2005-03-29 | 2010-07-28 | Arkal Medical Inc | Devices, systems, methods and tools for continuous glucose monitoring |
JP5301985B2 (en) | 2005-04-07 | 2013-09-25 | スリーエム イノベイティブ プロパティズ カンパニー | System and method for tool feedback sensing |
US8108023B2 (en) | 2005-04-11 | 2012-01-31 | Infotonics Technology Center, Inc. | Blood monitoring systems and methods thereof |
JP2006341089A (en) * | 2005-05-13 | 2006-12-21 | Fujikura Ltd | Instrument for carrying medicinal material and manufacturing method of the same |
US8048017B2 (en) * | 2005-05-18 | 2011-11-01 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
US8043250B2 (en) * | 2005-05-18 | 2011-10-25 | Nanomed Devices, Inc. | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
US20100193997A1 (en) * | 2005-06-10 | 2010-08-05 | Frederickson Franklyn L | Method of making a mold and molded article |
WO2007002523A2 (en) * | 2005-06-24 | 2007-01-04 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
EP2474338B1 (en) * | 2005-06-27 | 2013-07-24 | 3M Innovative Properties Company | Microneedle array applicator device |
AU2006261899B2 (en) | 2005-06-27 | 2012-05-10 | Kindeva Drug Delivery L.P. | Microneedle cartridge assembly and method of applying |
CN101232858B (en) | 2005-08-01 | 2011-08-24 | 华克医药科技有限公司 | Eradication of pigmentation and scar tissue |
US20070078414A1 (en) * | 2005-08-05 | 2007-04-05 | Mcallister Devin V | Methods and devices for delivering agents across biological barriers |
DE102005040251A1 (en) * | 2005-08-24 | 2007-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Transcorneal drug delivery system |
US20070056404A1 (en) * | 2005-09-14 | 2007-03-15 | Pricone Robert M | Method and apparatus for and to make hair removal elements |
EP1948139A4 (en) * | 2005-11-18 | 2012-04-04 | 3M Innovative Properties Co | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
US20080262416A1 (en) * | 2005-11-18 | 2008-10-23 | Duan Daniel C | Microneedle Arrays and Methods of Preparing Same |
KR100784848B1 (en) | 2005-12-09 | 2007-12-14 | 한국생산기술연구원 | microneedle for injection molding |
US9636035B2 (en) * | 2005-12-14 | 2017-05-02 | Scibase Ab | Medical apparatus for determination of biological conditions using impedance measurements |
US8632801B2 (en) | 2005-12-28 | 2014-01-21 | Alza Corporation | Stable therapeutic formulations |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US7658728B2 (en) * | 2006-01-10 | 2010-02-09 | Yuzhakov Vadim V | Microneedle array, patch, and applicator for transdermal drug delivery |
US20070179599A1 (en) * | 2006-01-31 | 2007-08-02 | Icon Medical Corp. | Vascular protective device |
WO2007115039A2 (en) | 2006-03-30 | 2007-10-11 | Valeritas, Llc | Multi-cartridge fluid delivery device |
WO2007124411A1 (en) * | 2006-04-20 | 2007-11-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
US20080063866A1 (en) * | 2006-05-26 | 2008-03-13 | Georgia Tech Research Corporation | Method for Making Electrically Conductive Three-Dimensional Structures |
DE102006028781A1 (en) | 2006-06-23 | 2007-12-27 | Robert Bosch Gmbh | Process for making porous microneedles and their use |
US8250729B2 (en) * | 2006-07-12 | 2012-08-28 | University Of Utah Research Foundation | 3D fabrication of needle tip geometry and knife blade |
KR100781702B1 (en) * | 2006-07-21 | 2007-12-03 | 연세대학교 산학협력단 | A hollow type microneedle and methods for preparing it |
KR100793615B1 (en) * | 2006-07-21 | 2008-01-10 | 연세대학교 산학협력단 | A biodegradable solid type microneedle and methods for preparing it |
WO2008020632A1 (en) * | 2006-08-18 | 2008-02-21 | Toppan Printing Co., Ltd. | Microneedle and microneedle patch |
DE102006040642A1 (en) * | 2006-08-30 | 2008-03-13 | Robert Bosch Gmbh | Microneedles for placement in the skin for transdermal application of pharmaceuticals |
US7785301B2 (en) * | 2006-11-28 | 2010-08-31 | Vadim V Yuzhakov | Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection |
US20080214987A1 (en) * | 2006-12-22 | 2008-09-04 | Nanomed Devices, Inc. | Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances |
US10525246B2 (en) | 2006-12-22 | 2020-01-07 | Nanomed Skincare, Inc. | Microdevice and method for transdermal delivery and sampling of active substances |
EP2121111B1 (en) | 2007-01-22 | 2018-03-14 | Corium International, Inc. | Applicators for microneedle arrays |
US7713196B2 (en) * | 2007-03-09 | 2010-05-11 | Nellcor Puritan Bennett Llc | Method for evaluating skin hydration and fluid compartmentalization |
JP5090032B2 (en) * | 2007-03-20 | 2012-12-05 | 凸版印刷株式会社 | Needle-like body and method for producing needle-like body |
JP4810486B2 (en) * | 2007-03-30 | 2011-11-09 | 富士フイルム株式会社 | Method and apparatus for producing functional film having high aspect ratio structure |
US9114238B2 (en) | 2007-04-16 | 2015-08-25 | Corium International, Inc. | Solvent-cast microprotrusion arrays containing active ingredient |
US20080269735A1 (en) * | 2007-04-26 | 2008-10-30 | Agustina Vila Echague | Optical array for treating biological tissue |
CA2695731C (en) | 2007-08-06 | 2018-04-03 | Transderm, Inc. | Microneedle arrays formed from polymer films |
US20120150023A1 (en) * | 2007-08-06 | 2012-06-14 | Kaspar Roger L | Microneedle arrays for active agent delivery |
JP5223278B2 (en) * | 2007-09-27 | 2013-06-26 | 凸版印刷株式会社 | Microneedle manufacturing method |
WO2009048607A1 (en) | 2007-10-10 | 2009-04-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
US8545467B2 (en) | 2007-12-07 | 2013-10-01 | Medela Holding Ag | Wound cover connecting device |
WO2009079589A2 (en) * | 2007-12-17 | 2009-06-25 | New World Pharmaceuticals, Llc | Integrated intra-dermal delivery, diagnostic and communication system |
EP2231257A4 (en) | 2007-12-24 | 2013-11-06 | Univ Queensland | Coating method |
EP2247527A4 (en) * | 2008-02-07 | 2014-10-29 | Univ Queensland | Patch production |
EP2100850A1 (en) * | 2008-03-11 | 2009-09-16 | Stichting Voor De Technische Wetenschappen | Microneedle array and a method for manufacturing microneedles |
JP5653750B2 (en) | 2008-03-12 | 2015-01-14 | 富士フイルム株式会社 | Method for producing an original plate, method for producing a concave array mold, method for producing an acicular array sheet, original plate |
US8591481B2 (en) | 2008-03-21 | 2013-11-26 | Ut-Battelle, Llc | Microfabricated instruments and methods to treat recurrent corneal erosion |
JP2011517850A (en) * | 2008-03-21 | 2011-06-16 | ライズ・テクノロジー・エッセ・アール・エル | Method for making microstructures by converting porous silicon into porous metals or ceramics |
JP2009233808A (en) * | 2008-03-27 | 2009-10-15 | Fujifilm Corp | Hollow needle sheet and manufacturing method for the same |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
WO2009140735A1 (en) | 2008-05-23 | 2009-11-26 | The University Of Queensland | Analyte detection by microneedle patch with analyte selective reagents. |
US9028463B2 (en) | 2008-06-30 | 2015-05-12 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device, and method for enhancing the efficacy of influenza vaccine by using microneedle device |
AU2009329806A1 (en) | 2008-12-22 | 2010-07-01 | The University Of Queensland | Patch production |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
US9113836B2 (en) | 2009-03-02 | 2015-08-25 | Seventh Sense Biosystems, Inc. | Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications |
KR101213223B1 (en) * | 2009-07-07 | 2013-01-09 | 한국전자통신연구원 | The method for manufacturing hallow microneedle structures |
KR101261466B1 (en) * | 2009-07-17 | 2013-05-10 | 한국전자통신연구원 | The method for manufacturing hallow micro needle structures |
GB2472778B (en) * | 2009-08-17 | 2014-11-19 | Barnet Medical Devices Ltd | A microneedle roller with a sterilising ultrasound generator and/or ultraviolet light |
AU2010286335B2 (en) * | 2009-08-26 | 2015-07-30 | The Bionics Institute Of Australia | Apparatus for stimulating and/or monitoring activity in tissue |
US8805467B2 (en) | 2009-10-30 | 2014-08-12 | Agency For Science, Technology And Research | Probe element and method of forming a probe element |
KR101251927B1 (en) * | 2010-01-22 | 2013-04-08 | 오형훈 | Fabrication Method of Microneedle |
WO2011094573A1 (en) | 2010-01-28 | 2011-08-04 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
EP2548608B1 (en) | 2010-03-19 | 2018-01-31 | CosMED Pharmaceutical Co., Ltd. | Proteoglycan-containing microneedle array |
KR101254240B1 (en) | 2010-12-17 | 2013-04-12 | 주식회사 라파스 | Process for preparing microstructures |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
PT2563450T (en) * | 2010-04-28 | 2017-08-28 | Kimberly Clark Co | Device for delivery of rheumatoid arthritis medication |
DK2563453T3 (en) | 2010-04-28 | 2017-05-22 | Kimberly Clark Co | Nano-patterned medical device with improved cellular interaction and process for its preparation |
WO2011137449A2 (en) | 2010-04-30 | 2011-11-03 | Seros Medical, Llc | Method and apparatus for treatment of ocular tissue using combined modalities |
JP6327852B2 (en) | 2010-05-04 | 2018-05-23 | コリウム インターナショナル, インコーポレイテッド | Methods and devices for transdermal delivery of parathyroid hormone using microprojection arrays |
WO2011163347A2 (en) | 2010-06-23 | 2011-12-29 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
WO2012006677A1 (en) | 2010-07-14 | 2012-01-19 | The University Of Queensland | Patch applying apparatus |
EP2593014B1 (en) | 2010-07-16 | 2015-11-04 | Seventh Sense Biosystems, Inc. | Low-pressure environment for fluid transfer devices |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
JP5672554B2 (en) * | 2010-08-19 | 2015-02-18 | Jcrファーマ株式会社 | Composition for subcutaneous or transdermal absorption |
JP5725435B2 (en) * | 2010-09-16 | 2015-05-27 | 国立大学法人豊橋技術科学大学 | Fine hole drilling tool, method for producing the same, and polymer film machining method |
EP2629836B1 (en) * | 2010-10-19 | 2018-09-12 | Trustees Of Tufts College | Silk fibroin-based microneedles and methods of making the same |
WO2012057270A1 (en) | 2010-10-27 | 2012-05-03 | Asti株式会社 | Jig for microneedle array placement and microneedle array device |
CN103370007B (en) | 2010-11-09 | 2018-12-18 | 第七感生物系统有限公司 | System and interface for blood sampling |
WO2012087352A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of California | Superhydrophobic and superoleophobic nanosurfaces |
US8591785B2 (en) * | 2011-01-10 | 2013-11-26 | Xerox Corporation | Digitally prepared stamp masters and methods of making the same |
US9005099B2 (en) | 2011-02-15 | 2015-04-14 | Seros Medical, Llc | Method and apparatus for the delivery of photochemical (cross-linking) treatment to scleral tissue |
JP5687170B2 (en) | 2011-03-30 | 2015-03-18 | コスメディ製薬株式会社 | Microneedle patch storage container |
WO2012149155A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
EP2701600B1 (en) | 2011-04-29 | 2016-06-08 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
KR20140034200A (en) | 2011-04-29 | 2014-03-19 | 세븐쓰 센스 바이오시스템즈, 인크. | Devices and methods for collection and/or manipulation of blood spots or other bodily fluids |
CN103717249B (en) | 2011-06-15 | 2017-03-22 | 克洛恩泰克制药股份公司 | Injection needle and device |
KR101314091B1 (en) * | 2011-07-26 | 2013-10-04 | 연세대학교 산학협력단 | Electro-microneedle assembly for cutaneous gene transfer in-situ and process for preparing the same |
JP2014524302A (en) * | 2011-08-16 | 2014-09-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Device for the treatment of eye diseases |
KR101990654B1 (en) | 2011-09-22 | 2019-06-18 | 코스메드 파마소티컬 씨오 쩜 엘티디 | Microneedle patch container |
US11179553B2 (en) | 2011-10-12 | 2021-11-23 | Vaxxas Pty Limited | Delivery device |
CN103889497A (en) | 2011-10-20 | 2014-06-25 | 考司美德制药株式会社 | Microneedle deposition technique |
EP2771059B1 (en) * | 2011-10-27 | 2019-07-17 | Sorrento Therapeutics, Inc. | Transdermal delivery of high viscosity bioactive agents |
JP5472770B2 (en) | 2012-02-17 | 2014-04-16 | コスメディ製薬株式会社 | Short melting microneedle |
WO2013129028A1 (en) * | 2012-02-29 | 2013-09-06 | 凸版印刷株式会社 | Needle-like material and method for manufacturing needle-like material |
AU2013243546A1 (en) * | 2012-04-03 | 2014-10-09 | Theraject, Inc. | Soluble microneedle arrays for buccal delivery of vaccines |
US9962535B2 (en) | 2012-05-11 | 2018-05-08 | 10X Technology Llc | Hollow silica glass microneedle arrays and method and apparatus for manufacturing same |
WO2013172929A1 (en) * | 2012-05-14 | 2013-11-21 | ARIZONA BOARD OF REGENTS, a body corporate of THE STATE OF ARIZONA acting for and on behalf of ARIZONE STATE UNIVERSITY | Minimally invasive stress sensors and methods |
KR101373739B1 (en) * | 2012-05-29 | 2014-03-14 | 포항공과대학교 산학협력단 | Microneedles array panel and manufacturing method thereof |
WO2013188640A1 (en) | 2012-06-14 | 2013-12-19 | Landy Toth | Devices, systems, and methods for diagnosis and treatment of overactive bladder |
ES2743733T3 (en) | 2012-06-15 | 2020-02-20 | Univ Washington Through Its Center For Commercialization | Wound closure devices based on microstructures |
JP5903016B2 (en) | 2012-06-27 | 2016-04-13 | コスメディ製薬株式会社 | Protective release sheet for microneedle patch |
US10980865B2 (en) | 2012-08-10 | 2021-04-20 | Aquavit Pharmaceuticals, Inc. | Direct application system and method for the delivery of bioactive compositions and formulations |
KR102240354B1 (en) | 2012-11-02 | 2021-04-14 | 코스메드 파마소티컬 씨오 쩜 엘티디 | Retinoic acid microneedle |
AU2013364053B2 (en) | 2012-12-21 | 2018-08-30 | Corium Pharma Solutions, Inc. | Microarray for delivery of therapeutic agent and methods of use |
BR122020006959B1 (en) | 2013-03-12 | 2022-04-26 | Corium, Inc | microprojection applicator |
BR112015022625B1 (en) | 2013-03-15 | 2023-01-31 | Corium, Inc | MICROSTRUCTURE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT |
MX2015011197A (en) | 2013-03-15 | 2016-03-04 | Aleyegn Inc | Scleral translocation elasto-modulation methods and apparatus. |
JP2016514133A (en) | 2013-03-15 | 2016-05-19 | コリウム インターナショナル, インコーポレイテッド | MICROARRAY CONTAINING FINE STRUCTURE CONTAINING NO POLYMER, MANUFACTURING METHOD AND USE METHOD |
CA2903459C (en) | 2013-03-15 | 2024-02-20 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
EP2968119B1 (en) | 2013-03-15 | 2019-09-18 | Corium International, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
WO2014182022A1 (en) | 2013-05-06 | 2014-11-13 | 연세대학교 산학협력단 | Method for manufacturing microstructure using centrifugal force and microstructure manufactured by same |
EP2994189A4 (en) * | 2013-05-06 | 2017-01-18 | Mupharma Pty Ltd | Non-invasive agent applicator |
JP6533520B2 (en) * | 2013-06-13 | 2019-06-19 | マイクロダーミクス インコーポレイテッドMicrodermics Inc. | Method of making metal microneedle |
EP3027263A1 (en) | 2013-07-30 | 2016-06-08 | ZP Opco, Inc. | Low-profile microneedle patch applicator |
GB2517707B (en) | 2013-08-28 | 2020-09-02 | Pci Biotech As | A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen |
CA2923010C (en) | 2013-09-03 | 2022-08-30 | Georgia Tech Research Corporation | Thermally stable vaccine formulations and microneedles |
AU2013400841B2 (en) | 2013-09-18 | 2018-12-13 | Cosmed Pharmaceutical Co., Ltd. | Microneedle patch application device and patch holder |
CN103624902B (en) * | 2013-12-09 | 2016-02-17 | 南通爱普医疗器械有限公司 | Micropin release method |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
GB201403773D0 (en) * | 2014-03-04 | 2014-04-16 | Univ Cardiff | Microneedle based cell delivery |
WO2015147040A1 (en) * | 2014-03-26 | 2015-10-01 | コスメディ製薬株式会社 | Microneedle staying in stratum corneum |
US9828284B2 (en) | 2014-03-28 | 2017-11-28 | Ut-Battelle, Llc | Thermal history-based etching |
US20160279401A1 (en) * | 2015-03-27 | 2016-09-29 | Allergan, Inc. | Dissolvable microneedles for skin treatment |
US20170056637A1 (en) | 2014-05-06 | 2017-03-02 | Mupharma Pty Ltd | Non-invasive agent applicator |
KR101501283B1 (en) * | 2014-05-28 | 2015-03-11 | 포항공과대학교 산학협력단 | Manufacturing method of microneedles array panel |
WO2016018148A1 (en) | 2014-07-30 | 2016-02-04 | Biomarque B.V. | Biosensor comprising a modified metal surface and method for the modification of a metal surface |
EP3188714A1 (en) | 2014-09-04 | 2017-07-12 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
WO2016054079A1 (en) | 2014-09-29 | 2016-04-07 | Zyomed Corp. | Systems and methods for blood glucose and other analyte detection and measurement using collision computing |
US9974471B1 (en) | 2014-10-24 | 2018-05-22 | Verily Life Sciences Llc | Analyte detection system and method for intradermal implantation of biocompatible optode nanosensors |
AU2015346003A1 (en) | 2014-11-12 | 2017-05-25 | Mupharma Pty Ltd | Non-invasive agent applicator |
CA2975275C (en) | 2015-02-02 | 2023-08-29 | Vaxxas Pty Limited | Microprojection array applicator and method |
JP6449057B2 (en) * | 2015-03-10 | 2019-01-09 | 国立研究開発法人産業技術総合研究所 | Method of substance introduction into cells using nanoneedle array |
US11654399B2 (en) * | 2015-03-17 | 2023-05-23 | President And Fellows Of Harvard College | Method for micromolding a polymeric membrane having a pore array |
JP2018512227A (en) | 2015-04-01 | 2018-05-17 | ノボ・ノルデイスク・エー/エス | Electroformed needle cannula |
CA3021580A1 (en) | 2015-06-25 | 2016-12-29 | Barry L. Merriman | Biomolecular sensors and methods |
WO2017004067A1 (en) | 2015-06-29 | 2017-01-05 | Corium International, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
US10098574B1 (en) | 2015-07-07 | 2018-10-16 | Verily Life Sciences Llc | Porous microneedles through sacrificial sugar incorporation, analyte detection system, and method for intradermal optode nanosensor implantation |
BR112018000955A2 (en) * | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | Application of mussel mucin product in the treatment and prevention of melanin-related diseases |
BR112018000953A2 (en) | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | Application of Mussel Mucin Products and Their Inhibition of Skin Inflammation |
WO2017011986A1 (en) | 2015-07-20 | 2017-01-26 | 赵兵 | Air filter |
CN108136176A (en) * | 2015-08-06 | 2018-06-08 | 加利福尼亚大学董事会 | The method that manufacture is used for the electrod-array of the transcutaneous electrostimulation of spinal cord |
WO2017028025A1 (en) | 2015-08-14 | 2017-02-23 | 江阴市本特塞缪森生命科学研究院有限公司 | Mussel adhesive protein product and use thereof for inhibiting mucosal inflammation |
US11103259B2 (en) | 2015-09-18 | 2021-08-31 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
EP3355981A4 (en) | 2015-09-28 | 2019-05-22 | Vaxxas Pty Limited | Microprojection arrays with enhanced skin penetrating properties and methods thereof |
KR101636069B1 (en) | 2015-12-08 | 2016-07-11 | 주식회사 라파스 | Manufacturing method of microstructure |
JP7280590B2 (en) | 2016-01-28 | 2023-05-24 | ロズウェル バイオテクノロジーズ,インコーポレイテッド | Methods and apparatus for measuring analytes using large-scale molecular electronics sensor arrays |
CN109328301B (en) | 2016-01-28 | 2021-03-12 | 罗斯韦尔生物技术股份有限公司 | Large-scale parallel DNA sequencing device |
JP6854532B2 (en) | 2016-02-09 | 2021-04-07 | ロズウェル バイオテクノロジーズ,インコーポレイテッド | Electronic, label-free DNA and genome sequencing |
US10597767B2 (en) | 2016-02-22 | 2020-03-24 | Roswell Biotechnologies, Inc. | Nanoparticle fabrication |
DK3423040T3 (en) * | 2016-03-01 | 2023-02-13 | Georgia Tech Res Inst | Microneedle particles and compositions for delivering a substance of interest |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
US9829456B1 (en) | 2016-07-26 | 2017-11-28 | Roswell Biotechnologies, Inc. | Method of making a multi-electrode structure usable in molecular sensing devices |
US20180092776A1 (en) | 2016-09-30 | 2018-04-05 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
EP3564672A4 (en) * | 2016-12-28 | 2020-09-09 | Nexmos Co., Ltd. | Method for fabricating microneedle-based diagnostic skin patch coated with aptamer and patch |
KR102622275B1 (en) | 2017-01-10 | 2024-01-05 | 로스웰 바이오테크놀로지스 인코포레이티드 | Methods and systems for DNA data storage |
US11197990B2 (en) * | 2017-01-18 | 2021-12-14 | Tc1 Llc | Systems and methods for transcutaneous power transfer using microneedles |
WO2018136148A1 (en) | 2017-01-19 | 2018-07-26 | Roswell Biotechnologies, Inc. | Solid state sequencing devices comprising two dimensional layer materials |
JP2020507422A (en) | 2017-02-17 | 2020-03-12 | アラーガン、インコーポレイテッドAllergan,Incorporated | Microneedle array containing active ingredients |
EP4306803A3 (en) | 2017-03-31 | 2024-04-10 | Vaxxas Pty Limited | Device and method for coating surfaces |
KR102692957B1 (en) | 2017-04-25 | 2024-08-06 | 로스웰 엠이 아이엔씨. | Enzyme circuits for molecular sensors |
US10508296B2 (en) | 2017-04-25 | 2019-12-17 | Roswell Biotechnologies, Inc. | Enzymatic circuits for molecular sensors |
EP4023764A3 (en) | 2017-05-09 | 2022-09-21 | Roswell Biotechnologies, Inc. | Binding probe circuits for molecular sensors |
JP7038739B2 (en) * | 2017-05-17 | 2022-03-18 | マサチューセッツ インスティテュート オブ テクノロジー | Self-restoring goods |
US11541015B2 (en) | 2017-05-17 | 2023-01-03 | Massachusetts Institute Of Technology | Self-righting systems, methods, and related components |
US10921303B1 (en) | 2017-05-31 | 2021-02-16 | Iowa State University Research Foundation, Inc. | Miniature sensors with probe insertable into and for obtaining measurements from plants and a variety of other mediums |
US11175128B2 (en) | 2017-06-13 | 2021-11-16 | Vaxxas Pty Limited | Quality control of substrate coatings |
EP4218893A1 (en) | 2017-08-04 | 2023-08-02 | Vaxxas Pty Limited | Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (map) |
WO2019046589A1 (en) | 2017-08-30 | 2019-03-07 | Roswell Biotechnologies, Inc. | Processive enzyme molecular electronic sensors for dna data storage |
WO2019075100A1 (en) | 2017-10-10 | 2019-04-18 | Roswell Biotechnologies, Inc. | Methods, apparatus and systems for amplification-free dna data storage |
EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
CN108939280B (en) * | 2018-04-13 | 2021-05-18 | 杭州电子科技大学 | Preparation method of SU8 microneedle array patch |
CA3100710A1 (en) | 2018-05-17 | 2019-11-21 | Massachusetts Institute Of Technology | Systems for electrical stimulation |
EP3795205B1 (en) * | 2018-05-18 | 2023-10-04 | Postech Academy-Industry Foundation | Method for manufacturing a transdermal drug delivery patch |
US12036378B2 (en) | 2018-05-18 | 2024-07-16 | Postech Academy-Industry Foundation | Transdermal drug delivery patch and manufacturing method thereof |
US20220047190A1 (en) * | 2018-09-10 | 2022-02-17 | Unm Rainforest Innovations | Color Changing Detection Patch Utilizing Microneedle Sampling of Interstitial Fluid |
KR102227989B1 (en) * | 2018-09-18 | 2021-03-15 | 한국기계연구원 | Microstructure-based drug injection device and manufacturing method thereof |
KR102039582B1 (en) | 2018-12-12 | 2019-11-01 | 주식회사 라파스 | Method for testing compatibility of microneedle material and manufacturing method of microneedle comprising the same |
US11771829B2 (en) | 2019-02-01 | 2023-10-03 | Massachusetts Institute Of Technology | Systems and methods for liquid injection |
CN110478613B (en) * | 2019-08-22 | 2022-08-09 | 京东方科技集团股份有限公司 | Device for delivering a formulation, apparatus and method of making a needle array in a device |
CN110787361B (en) * | 2019-10-30 | 2021-08-31 | 西北工业大学 | Hollow inclined metal microneedle array and manufacturing method thereof based on SU-8 mold |
US11541216B2 (en) | 2019-11-21 | 2023-01-03 | Massachusetts Institute Of Technology | Methods for manufacturing tissue interfacing components |
US20210196141A1 (en) * | 2019-12-27 | 2021-07-01 | RichHealth Technology Corporation | Wearable sensing device |
CN111228643A (en) * | 2020-02-12 | 2020-06-05 | 成都工业学院 | Hollow microneedle array device and manufacturing method thereof |
US11202753B1 (en) | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
NL2026676B1 (en) * | 2020-10-15 | 2022-06-14 | Cytosurge Ag | A method of manufacturing a micro-fluidic probe |
US20230277762A1 (en) * | 2022-03-01 | 2023-09-07 | Insulet Corporation | Single package automated drug delivery system |
EP4383011A1 (en) * | 2022-12-07 | 2024-06-12 | Patek Philippe SA Genève | Micromechanical timepiece part and method for manufacturing same |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE25637E (en) * | 1964-09-08 | Means for vaccinating | ||
US3123212A (en) * | 1964-03-03 | Multiple disposable intracutaneous injector package | ||
US2893392A (en) * | 1958-01-08 | 1959-07-07 | American Cyanamid Co | Article of manufacture for intracutaneous injections |
GB885036A (en) * | 1958-12-10 | 1961-12-20 | Allen & Hanburys Ltd | Improvements relating to surgical multiple puncture devices |
US3034507A (en) * | 1960-05-10 | 1962-05-15 | American Cyanamid Co | Intracutaneous injection device |
US3136314A (en) * | 1960-08-01 | 1964-06-09 | Kravitz Harvey | Vaccinating devices |
US3221739A (en) * | 1962-03-26 | 1965-12-07 | Rosenthal Sol Roy | Injection device |
US3221740A (en) * | 1962-08-31 | 1965-12-07 | Rosenthal Sol Roy | Injection device |
US3556080A (en) * | 1968-04-08 | 1971-01-19 | Lincoln Lab Inc | Skin allergy testing device |
US3596660A (en) * | 1969-05-12 | 1971-08-03 | Illinois Tool Works | Injection device |
US3675766A (en) * | 1970-02-04 | 1972-07-11 | Sol Roy Rosenthal | Multiple puncture injector device |
US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
FR2232331B1 (en) * | 1973-06-06 | 1978-03-24 | Guerin A Ets | |
OA05448A (en) * | 1975-10-16 | 1981-03-31 | Manufrance Manufacture Francai | Multi-penetrating vaccine device. |
US4159659A (en) * | 1978-05-16 | 1979-07-03 | Carol Nightingale | Electrical marking device |
US4222392A (en) * | 1979-05-23 | 1980-09-16 | Alier-Screen, Inc. | Allergy testing device with vented base |
US4320758A (en) * | 1979-05-07 | 1982-03-23 | Alza Corporation | Osmotically driven fluid dispenser |
CA1247960A (en) * | 1983-03-24 | 1989-01-03 | Hideki Aoki | Transcutaneously implantable element |
US4921475A (en) * | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US5865786A (en) * | 1983-08-18 | 1999-02-02 | Drug Delivery Systems, Inc. | Programmable control and mounting system for transdermal drug applicator |
US4664651A (en) * | 1985-03-01 | 1987-05-12 | The Procter & Gamble Company | Subatmospheric method and apparatus for expanding blood vessels to facilitate puncture with a cannula |
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4775361A (en) * | 1986-04-10 | 1988-10-04 | The General Hospital Corporation | Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport |
US5335670A (en) * | 1986-04-18 | 1994-08-09 | Henry Fishman | Allergy testing method and apparatus |
US4969468A (en) * | 1986-06-17 | 1990-11-13 | Alfred E. Mann Foundation For Scientific Research | Electrode array for use in connection with a living body and method of manufacture |
US4703761A (en) * | 1986-08-04 | 1987-11-03 | Rathbone R Rodion | Blood sampling device for obtaining small quantity of venous blood |
US4771660A (en) * | 1987-08-24 | 1988-09-20 | Harold Yacowitz | Needle holder |
US4798582A (en) * | 1987-10-27 | 1989-01-17 | Permark Corp. C/O Sci/Med Advances Corp. | Needle cartridge |
US5147355A (en) * | 1988-09-23 | 1992-09-15 | Brigham And Womens Hospital | Cryoablation catheter and method of performing cryoablation |
EP0429842B1 (en) * | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
US5697901A (en) * | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
US5054339A (en) * | 1990-02-20 | 1991-10-08 | Harold Yacowitz | Tattooing assembly |
US5858188A (en) * | 1990-02-28 | 1999-01-12 | Aclara Biosciences, Inc. | Acrylic microchannels and their use in electrophoretic applications |
US5138220A (en) * | 1990-12-05 | 1992-08-11 | Science Applications International Corporation | Field emission cathode of bio-molecular or semiconductor-metal eutectic composite microstructures |
US5527288A (en) * | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5279544A (en) * | 1990-12-13 | 1994-01-18 | Sil Medics Ltd. | Transdermal or interdermal drug delivery devices |
TW279133B (en) * | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
US5605662A (en) * | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
JP3368603B2 (en) * | 1992-02-28 | 2003-01-20 | オリンパス光学工業株式会社 | Gene therapy treatment device |
WO1993020784A1 (en) * | 1992-04-10 | 1993-10-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
US5279552A (en) * | 1993-01-11 | 1994-01-18 | Anton Magnet | Intradermal injection device |
US5383512A (en) * | 1993-01-27 | 1995-01-24 | Midwest Research Institute | Method for fabricating a substrate having spaced apart microcapillaries thereon |
US5401242A (en) * | 1993-02-25 | 1995-03-28 | Yacowitz; Harold | Apparatus for injecting a substance into the skin |
US5582184A (en) * | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5618295A (en) * | 1993-10-16 | 1997-04-08 | Samsung Electro-Mechanics Co., Ltd. | Apparatus for preparing skin in advance |
US5885211A (en) * | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
ATE231733T1 (en) * | 1994-01-21 | 2003-02-15 | Powderject Vaccines Inc | GAS ACTUATED ELEMENT FOR DISCHARGING GENETIC MATERIAL |
US5457041A (en) * | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
US5899880A (en) * | 1994-04-08 | 1999-05-04 | Powderject Research Limited | Needleless syringe using supersonic gas flow for particle delivery |
KR0134152B1 (en) * | 1994-05-23 | 1998-04-14 | 이형도 | Skin treatment device for medication |
US5611806A (en) * | 1994-05-23 | 1997-03-18 | Samsung Electro-Mechanics Co., Ltd. | Skin perforating device for transdermal medication |
US5591139A (en) * | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
IE72524B1 (en) * | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
GB9422260D0 (en) * | 1994-11-04 | 1994-12-21 | Owen Mumford Ltd | Improvements relating to skin prickers |
ATE177325T1 (en) * | 1994-12-09 | 1999-03-15 | Novartis Erfind Verwalt Gmbh | TRANSDERMAL SYSTEM |
US5599302A (en) * | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5611942A (en) * | 1995-03-02 | 1997-03-18 | Kabushiki Kaisha Toshiba | Method for producing tips for atomic force microscopes |
AU5740496A (en) * | 1995-05-22 | 1996-12-11 | General Hospital Corporation, The | Micromechanical device and method for enhancing delivery of compounds through the skin |
DE19525607A1 (en) * | 1995-07-14 | 1997-01-16 | Boehringer Ingelheim Kg | Transcorneal drug delivery system |
US5658515A (en) * | 1995-09-25 | 1997-08-19 | Lee; Abraham P. | Polymer micromold and fabrication process |
US5758505C1 (en) * | 1995-10-12 | 2001-10-30 | Cryogen Inc | Precooling system for joule-thomson probe |
US5883211A (en) * | 1996-01-19 | 1999-03-16 | Aclara Biosciences, Inc. | Thermoreversible hydrogels comprising linear copolymers and their use in electrophoresis |
US5801057A (en) * | 1996-03-22 | 1998-09-01 | Smart; Wilson H. | Microsampling device and method of construction |
ES2200187T3 (en) * | 1996-07-03 | 2004-03-01 | Altea Therapeutics Corporation | MULTIPLE MECHANICAL MICROPORATION OF THE SKIN OR MUCOSA. |
US5699157A (en) * | 1996-07-16 | 1997-12-16 | Caliper Technologies Corp. | Fourier detection of species migrating in a microchannel |
US5911223A (en) * | 1996-08-09 | 1999-06-15 | Massachusetts Institute Of Technology | Introduction of modifying agents into skin by electroporation |
US5876675A (en) * | 1997-08-05 | 1999-03-02 | Caliper Technologies Corp. | Microfluidic devices and systems |
KR100572539B1 (en) * | 1997-12-11 | 2006-04-24 | 알자 코포레이션 | Device for enhancing transdermal agent flux |
US6669663B1 (en) * | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
US20010053891A1 (en) * | 1999-12-30 | 2001-12-20 | Ackley Donald E. | Stacked microneedle systems |
-
1999
- 1999-06-10 EP EP99928580A patent/EP1086214B1/en not_active Expired - Lifetime
- 1999-06-10 JP JP2000553570A patent/JP2002517300A/en active Pending
- 1999-06-10 WO PCT/US1999/013226 patent/WO1999064580A1/en active IP Right Grant
- 1999-06-10 AU AU45616/99A patent/AU767122B2/en not_active Ceased
- 1999-06-10 CA CA002330207A patent/CA2330207C/en not_active Expired - Fee Related
-
2001
- 2001-12-06 US US10/010,723 patent/US20020138049A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11931040B2 (en) | 2016-03-01 | 2024-03-19 | Kitotech Medical, Inc. | Microstructure-based systems, apparatus, and methods for wound closure |
US11986613B2 (en) | 2020-02-19 | 2024-05-21 | Kitotech Medical, Inc. | Microstructure systems and methods for pain treatment |
US11957346B2 (en) | 2022-02-18 | 2024-04-16 | Kitotech Medical, Inc. | Force modulating deep skin staples and instruments |
Also Published As
Publication number | Publication date |
---|---|
JP2002517300A (en) | 2002-06-18 |
AU4561699A (en) | 1999-12-30 |
AU767122B2 (en) | 2003-10-30 |
CA2330207A1 (en) | 1999-12-16 |
EP1086214A4 (en) | 2007-05-02 |
EP1086214B1 (en) | 2009-11-25 |
EP1086214A1 (en) | 2001-03-28 |
WO1999064580A1 (en) | 1999-12-16 |
US20020138049A1 (en) | 2002-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2330207C (en) | Microneedle devices and methods of manufacture and use thereof | |
US8708966B2 (en) | Microneedle devices and methods of manufacture and use thereof | |
US6743211B1 (en) | Devices and methods for enhanced microneedle penetration of biological barriers | |
US7344499B1 (en) | Microneedle device for extraction and sensing of bodily fluids | |
EP1187653B1 (en) | Devices for enhanced microneedle penetration of biological barriers | |
US9302903B2 (en) | Microneedle devices and production thereof | |
EP1471953B1 (en) | Gas pressure actuated microneedle arrays, and systems and methods relating to same | |
US20030135166A1 (en) | Switchable microneedle arrays and systems and methods relating to same | |
US20030135167A1 (en) | Microneedles, microneedle arrays, and systems and methods relating to same | |
AU2005200910B2 (en) | Devices and methods for enhanced microneedle penetration of biological barriers | |
AU2004200303B2 (en) | Microneedle devices and methods of manufacture and use thereof | |
CA2510389A1 (en) | Microneedle devices and methods of manufacture and use thereof | |
AU2008200252A1 (en) | Microneedle devices and methods of manufacture and use thereof | |
AU2002253812A1 (en) | Microneedle devices and production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170612 |